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Summary
Background—The Millennium Declaration in 2000 brought special global attention to HIV,
tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6.
The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to
disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated
progress has occurred since the Millennium Declaration.
Methods—To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model
appropriately modified based on a systematic review of available studies of mortality with and
without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models
to fit vital registration data corrected for misclassification of HIV deaths. In generalised
epidemics, we minimised a loss function to select epidemic curves most consistent with
prevalence data and demographic data for all-cause mortality. We analysed counterfactual
scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission
(PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to
estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-
notifications, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-
specific mortality using Bayesian meta-regression to generate consistent trends in all parameters.
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We analysed malaria mortality and incidence using an updated cause of death database, a
systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010–13)
of incidence, drug resistance, and coverage of insecticide-treated bednets.
Findings—Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty
interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3
million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 million
deaths (1·6 million to 1·9 million). Concentrated epidemics in Latin America and eastern Europe
are substantially smaller than previously estimated. Through interventions including PMTCT and
ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 76·1)
in developing countries. From 2000 to 2011, the ratio of development assistance for health for
HIV to years of life saved through intervention was US$4498 in developing countries. Including
in HIV-positive individuals, all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7
million), prevalence was 11·9 million (11·6 million to 12·2 million), and number of deaths was 1·4
million (1·3 million to 1·5 million) in 2013. In the same year and in only individuals who were
HIV-negative, all-form tuberculosis incidence was 7·1 million (6·9 million to 7·3 million),
prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 1·3 million
(1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and
death became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately
occurs in men and boys (versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of
deaths (60·8 to 70·3). Globally, malaria cases and deaths grew rapidly from 1990 reaching a peak
of 232 million cases (143 million to 387 million) in 2003 and 1·2 million deaths (1·1 million to 1·4
million) in 2004. Since 2004, child deaths from malaria in sub-Saharan Africa have decreased by
31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing since
1990.
Interpretation—Our estimates of the number of people living with HIV are 18·7% smaller than
UNAIDS’s estimates in 2012. The number of people living with malaria is larger than estimated
by WHO. The number of people living with HIV, tuberculosis, or malaria have all decreased since
2000. At the global level, upward trends for malaria and HIV deaths have been reversed and
declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) still
have increasing HIV incidence. Substantial progress since the Millennium Declaration is an
encouraging sign of the effect of global action.
Funding—Bill & Melinda Gates Foundation.
Introduction
The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis,
and malaria through the formulation of Millennium Development Goal 6 (MDG 6). The
high priority status of these three diseases in the development community was confirmed
through the creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria in 2002.
Bilateral initiatives such as the President’s Emergency Plan for AIDS Relief and the
President’s Malaria Initiative also added substantial new resources. From 2000 to 2011,
multilaterals, bilaterals, foundations, and non-governmental organisations have invested US
$51·6 billion for HIV, $11·3 billion for malaria, and $8·3 billion for tuberculosis (price in
2011 US dollars) in development assistance for health (DAH).1 Substantial benefits of these
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investments have been documented in several studies.2-9 In the lead up to the MDG deadline
of 2015 and amid the global debate on development goals post-2015, important questions
have been raised about the advantages and disadvantages of maintaining focus on these three
diseases.5,10-18 The rise of the importance of non-communicable diseases in some regions of
the developing world19-26 have led to calls for goals that cover a broader range of
diseases.10,15,17,19,20,24,25,27,28 At the same time, ambitious goals of zero tuberculosis
incidence and deaths and zero HIV incidence and deaths have been formulated by some
groups;29-34 the Secretary-General of the UN had already established a goal of zero malaria
deaths by 2015.35 Understanding the distribution and trends of these three diseases and how
they have been affected by the MDG era is an important input to this wider debate.12,36
Because of their prominence, there are major UN efforts on an annual basis to track the
epidemiology of these three diseases. UNAIDS now produces country estimates of HIV
incidence, prevalence, and death every year.37 Over many years, they have developed a
sophisticated modelling approach to track the epidemic—their primary input in generalised
epidemics is annual antenatal clinic sero-surveillance data and periodic household surveys
that include blood testing.38,39 The annual Global Tuberculosis Report from the World
Health Organization (WHO) provides estimates of incidence and deaths from tuberculosis
by country. Crucial inputs to the assessment of incidence are case notifications and national
expert opinion on the case-detection rate, and separate modelling of cause of death data from
vital registration systems and verbal autopsy studies. For the World Malaria Report, WHO
uses a complicated strategy to estimate incidence and mortality that varies by region and age
group. For child malaria deaths in sub-Saharan Africa, the main inputs are verbal autopsy
studies and estimated malaria risk. Estimates are adjusted post-hoc for coverage of
insecticide-treated bednets (ITNs). Outside of sub-Saharan Africa and for low-transmission
countries in Africa reported case numbers are combined with an assumed case-fatality rate.
These three efforts have provided important insights into the geographical distribution and
likely trends in the diseases.
Despite these efforts, extraordinary uncertainty exists at the country-level in the burden of
all three. The burdens of HIV and malaria are concentrated in sub-Saharan Africa; countries
that, other than South Africa, have very poor vital registration and incomplete notification
systems. Tuberculosis is concentrated in Asia and southern Africa where a few more
countries have better data systems but there are still huge gaps in information. Modelling
strategies for tracking the diseases have evolved to be necessarily complex in view of the
incomplete and often conflicting nature of the data. For HIV and malaria, UN modelling
efforts explicitly use information about intervention delivery and assumed benefits of
intervention. The distinction between data for disease outcomes and data for intervention
coverage driving the results of these efforts is blurred. In the more complex modelling
strategies, the compounded effect of uncertainty about different parameters can be hard to
characterise. Efforts to model the three diseases are largely independent of each other—the
exception is recent coordinated efforts to understand the intersection of tuberculosis and
HIV.40
The Global Burden of Disease 2010 Study provided a comprehensive update on levels and
trends of a large number of diseases, injuries, and risk factors for 187 countries from 1990 to
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2010.41-48 The Global Burden of Disease collaboration is now generating annual updates,
the first of which is the Global Burden of Disease, Injuries, and Risk Factors Study 2013
(GBD 2013). The GBD 2013 provides an opportunity to examine the evidence on the levels
and trends in the three MDG 6 diseases within the comprehensive and coherent framework
of the GBD. Compared with GBD 2010, we have given special emphasis in the GBD 2013
to incorporate new data, to more rigorously identify and incorporate further key sources of
uncertainty, and to incorporate adjustments for the biases that are present in different data
sources. A crucial aspect of the GBD effort is to quantify time trends; comparing trends
from 1990 to 2000 and from 2000 to 2013 provides an opportunity to see if there has been
accelerated progress since the Millennium Declaration. The GBD 2013 supersedes all
previously published GBD results.
Methods
Overview
The overall conceptual and analytical framework for the GBD is described elsewhere.41-48
Major refinements of the analytical approach for different diseases and risk factors are
explored in other papers.49-51 We summarise here the methods used for the analysis of the
three diseases, emphasising refinements since the GBD 2010. All refinements in methods
have been applied to the full 1990–2013 time series to ensure comparability of results.
Metadata for input sources used in the GBD 2013 will be available in the Global Health
Data Exchange on publication of the full GBD 2013 results.
HIV
For the GBD 2010, we primarily used estimates of prevalence and mortality developed by
UNAIDS. The main modification was the requirement that the sum of cause-specific
mortality from each cause in a country, age, sex, and year group equalled the estimate of all-
cause mortality for that country, age, and sex group generated through the analysis of
demographic sources.43 Modifications of HIV deaths through this internal consistency
process did not lead to revisions of incidence or prevalence for HIV in a particular age-sex-
country-year. For the GBD 2013, we have sought to develop a set of estimates of incidence,
prevalence, and mortality from HIV that are internally consistent with each other and also
meet the GBD requirement that the sum of each cause of death equals all-cause mortality.
Internally consistent means the incidence, prevalence, and death figures are mathematically
possible given that prevalence is a function of past incidence, remission, and death rates for
any age cohort.
Modified Spectrum Model—UNAIDS uses two key analytical components in their
epidemiological estimation. The Estimation and Projections Package (EPP) is used to
estimate incidence trajectories that are consistent with prevalence surveys and other
prevalence measurements such as antenatal clinic serosurveillance.52 Spectrum is a
compartmental HIV progression model used to generate age-specific incidence, prevalence,
and death rates from the EPP incidence curves and assumptions about intervention scale-up
and local variation in epidemiology.53 We have recoded Spectrum in Python, an open source
higher level language that can easily be run on a parallelised computational cluster,
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following the exact structure of Spectrum to facilitate faster computation required for the
uncertainty analysis and consistency analysis with all-cause mortality. We have also made
four important modifications to the assumptions.
First, we have altered the Spectrum assumptions about mortality without antiretroviral
therapy (ART). Following UNAIDS assumptions, mortality is modelled as shown in figure
1. The death and progression rates between CD4 categories vary by age according to four
age-groups, 15–24 years, 25–34 years, 35–44 years, and 45 years or older. UNAIDS
estimates a single set of progression and death rates by first fitting a Weibull distribution to
data from three east African seroconverter cohorts from the ALPHA network and one
miners cohort from South Africa,54 and then selecting a set of progression and death rates in
Excel Solver that minimises the sum of the squared differences between the predicted and
Weibull survival probabilities.55,56 Uncertainty in their estimates for this component was
approximated by assuming a coefficient of variation of 0·05 for each mortality rate. To
better characterise uncertainty in the progression and death rates, we systematically
reviewed the literature on mortality without ART. We searched terms related to pre-ART or
ART-naive survival since seroconversion—exact search terms are in the appendix (p 132).
After screening, we identified 13 cohort studies that included the cohorts used by UNAIDS
from which we extracted survival at each 1-year point after infection. We modelled the logit
of the conditional probability of death between years in these studies using the following
formula:
In the formula, m is conditional probability of death from year tj to tj+1, ai is an indicator
variable for age group at seroconversion (15–24 years, 25–34 years, 35–44 years, and 45
years or older), tj is an indicator variable of year since seroconversion, and uκ is a study-
level random effect. By sampling the variance-covariance matrix of the regression
coefficients and the study level random effect, we generated 1000 survival curves for each
age group that capture the systematic variation in survival across the available studies
(figure 2, appendix p 18). Across all age groups, median survival ranges from 3·6 years to
29·5 years. For each of the 1000 survival curves, we use the UNAIDS optimisation
framework to find a set of progression and death rates that minimises the sum of the squared
errors for the fit to the survival curve. For the death rates generated from the optimisation,
the coefficient of variation across the set of 1000 is 0·44–1·00 depending on the age-group,
which is substantially higher than the UNAIDS assumption of 0·05.
Second, for mortality on ART, UNAIDS used data from five regional cohorts from the
IeDEA network to directly estimate death rates by age, sex, and CD4 count, which have
been used as the default for all countries in a region.57,58 Through their country consultation
process some of these defaults have been modified. For example, Myanmar assumes a
constant mortality rate by initial CD4 group, without any variation by age, sex, or time on
treatment. To better characterise real variation in the death rates on ART across
programmes, we searched the published literature. Using the terms “HIV”, “mortality”, and
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“antiretroviral therapy” we identified 4996 titles. Screening the abstracts and papers yielded
102 total papers for extraction (appendix p 133). These included mortality and loss to
follow-up data for 80 cohorts, age hazard ratios for 40 cohorts, and sex hazard ratios for 86
cohorts. We corrected reported probabilities of death for loss to follow-up using an update of
the approach developed by Verguet and colleagues.59 Verguet and colleagues used tracing
and follow-up studies to empirically estimate the relation between death in loss to follow-up
and the rate of loss to follow-up. We used DisMod-MR 2.0 to do a meta-regression of the
data for on-ART mortality by initial CD4 count separately for high-income countries, GBD
developing countries outside of sub-Saharan Africa, and sub-Saharan Africa (appendix p 7).
We meta-analysed region-specific age hazard ratios using DisMod-MR 2.0, and region-
specific sex hazard ratios using the Stata command metan. The age and sex hazard ratios
were applied to the CD4-specific mortality rates, accounting for the distribution of ages and
sexes in the mortality data. We used 1000 draws from the posterior distribution for each age,
sex, and CD4 category for conditional probabilities of death for 0–6 months, 7–12 months,
and 13–24 months after initiation of ART as inputs to Spectrum. Table 1 shows HIV-
specific mortality rates for people aged 25–34 years on ART in sub-Saharan Africa (see
appendix pp 136–38 for HIV-specific mortality for other age groups and regions).
Third, to better capture variation in the age-pattern of incidence, we used the UNAIDS
distributions of the relative incidence by age prepared for UNAIDS based on selected cohort
studies. To capture the possibility that there is greater variation across countries in the age
incidence pattern than in these studies, we increased the uncertainty ranges by an arbitrary
50%.
Fourth, for all other input parameters including the number of individuals receiving ART,
prevention of mother-to-child transmission (PMTCT), or co-trimoxazole prophylaxis, we
randomly sampled a uniform distribution from 0·9 to 1·1 and used the draw to adjust each
parameter. For the sex ratio of incidence, we sampled a wider but arbitrary range from 0·8 to
1·2, because the demographic data in many generalised epidemics indicate that there is less
of a difference between the sexes than seen in the population prevalence surveys.
Generalised epidemics—UNAIDS identified 41 countries as generalised epidemics; this
distinction is important because for these epidemics the primary sources of information
about prevalence come from antenatal clinic serosurveillance and household surveys. In
addition to these 41 countries, we have included in this category Senegal, Niger, and India
because of the availability of population-based surveys. Prevalence data from countries with
generalised epidemics has been analysed by UNAIDS using EPP to generate 1000 samples
of incidence curves for people aged 15–49 years consistent with the prevalence data. For
each of these 1000 incidence curves, we randomly sampled the parameter distributions for
all input parameters ten times to generate 10 000 epidemic curves of incidence, prevalence,
and death by age and sex. The selection of 10 000 iterations was based on testing that it
would ensure stable uncertainty intervals. Some of these 10 000 death curves exceed in one
or more age-sex-year groups the estimate of all-cause mortality based on demographic
sources. Because the demographic estimates of all-cause mortality are based on substantial
empirical data, these HIV epidemic curves are unlikely to represent reality. These
mismatches occur more often in southern Africa. We identified the 250 modified Spectrum
Murray et al. Page 6













curves and all-cause mortality curves that are most consistent with each other. We define a
loss function using the following formula:
For run r of a given country, excess mortality, e, is equal to the sum of all non-zero
differences between HIV mortality, mHIV, and 0·8 times a randomly selected all-cause
mortality draw, mall-cause, across all year-age-sex combinations (t, a, and s, respectively).
We compared the Spectrum estimates to 0·8 times the all-cause estimates because this is the
highest recorded fraction of deaths in any age-group in any country’s cause of death data
due to HIV. We randomly paired each of the 10 000 modified spectrum outputs with one of
the 1000 all-cause mortality curves generated from the demographic analysis. The 250 pairs
that minimised the loss function were selected. When more than 250 have a loss function
equal to zero, we randomly chose among this set. We resampled the 250 draws to 1000; 250
are used with resampling for computational convenience. The appendix (pp 18–20) shows
mortality at ages 15–59 years from the full set of 10 000 modified spectrum models and the
subset that is selected through the matching process for Uganda, South Africa, and Ghana.
Demographic data matching selects in South Africa epidemic curves that are at the low end
of the distribution with longer median survival; in Uganda this effect is slightly less
pronounced and in Ghana pre-matching and post-matching were identical.
Concentrated epidemics with vital registration data—UNAIDS estimates for
concentrated epidemics depend critically on two inputs: first, the assessment of prevalence
of HIV in high-risk groups (people who inject drugs, men who have sex with men, and
female sex workers) for which there is much information in many countries;60-72 and
second, assumptions on the percentage of the population in high-risk groups. Although there
is guidance on measurement,73 real data in most countries are limited. In many countries,
UNAIDS estimates are based on local opinion. Resulting assumptions have been highly
variable across countries. For example, Uruguay defines 4·5% of its population as men who
have sex with men while neighbouring Argentina defines only 1% of its population as men
who have sex with men. An alternative source in many countries is cause of death data from
national vital registration systems. To track the epidemic using cause of death data can
require up to three important adjustments. First, in some middle-income countries, vital
registration is incomplete. Wang and colleagues have used death distribution methods43 to
assess completeness in all countries with vital registration; we have used this information to
correct upwards incomplete registration. Second, a key aspect of the GBD is to redistribute
deaths that are assigned to immediate or intermediate causes of death rather than underlying
causes of death (garbage codes).74 In addition to garbage codes, because HIV was not
included in the International Classification of Diseases (ICD)-9 until 1986 and not
implemented in many countries until later, deaths were often assigned to other codes such as
graft versus host disease or Kaposi’s sarcoma. Third, in some places, because of stigma or
misdiagnosis, HIV deaths can be assigned to other underlying causes of death such as
tuberculosis, endocrine disorders, meningitis, or encephalitis. Birnbaum and colleagues
developed a method to identify these misclassified deaths.75 We applied this method to all
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countries. Misclassification of HIV deaths in Birnbaum and colleagues’ method is based on
fulfilling three criteria. First, the temporal trend for a cause should coincide with the HIV
epidemic. Second, the pattern of the relative death rate by age should shift towards the ages
of 15–49 years during the epidemic years. Third, the temporal and age-pattern shifts cannot
be explained by other known epidemiological trends. Applying these methods, we transfer
deaths from 47 causes in 52 countries. Figure 3 shows the number of HIV deaths directly
coded to HIV, the number of deaths re-assigned to HIV from garbage code redistribution,
and the number of deaths from the application of the HIV misclassification method for
Thailand and Russia. The height of the bar is the final number of deaths in each age group.
For countries with corrected vital registration, we imputed missing years of data to generate
a complete time series for HIV from the estimated start year of the epidemic using spatial-
temporal Gaussian Process Regression (ST-GPR).43,76,77 ST-GPR using a linear mean
function and a Matern covariance has been widely used for time-series estimation in global
health descriptive studies such as for tobacco prevalence, obesity prevalence, or child and
adult mortality. To generate an internally consistent set of incidence, prevalence, and death
curves with uncertainty, we used the observed HIV death numbers to calibrate the modified
Spectrum models. First, we started with a modified Spectrum model constructed based on
the analysis of high-risk groups— where no high-risk group analysis was available we used
a regional default model. Second, for each of the 1000 draws from this model, we modified
the incidence at time t by the ratio of observed deaths to modified spectrum deaths at time t
+λ, where λ is the lag between incidence and death. We drew from a distribution of lags of
10-15 years to generate 6000 different adjusted incidence curves. For incidence for the last λ
time periods, we drew a random weight between 0 and 1 from a uniform distribution and
used it to calculate a weighted average of adjusted incidence in year t + λ and unadjusted
incidence multiplied by the deaths ratio in year t + λ. Using these modified incidence curves,
we reran the modified Spectrum generating 6000 possible epidemic curves. As a final step,
for each of these 6000 we computed the mean squared error of predicted deaths compared
with observed deaths. The 1000 curves with the lowest mean squared error were selected as
the final set for analysis. Figure 4 shows the results of this process for Panama and the
comparison with the UNAIDS high-risk group analysis; the corrected vital registration data
suggest a much smaller epidemic with different timing.
Concentrated epidemics with high-risk group analysis and insufficient or no
cause of death data—There were 17 countries with concentrated epidemics where we
had no or insufficient vital registration or verbal autopsy data to inform our cause of death
analysis. For these countries we ran modified Spectrum to output 1000 draws of incidence,
randomly selecting 1000 time series of the death ratios generated in the process described
above, and multiplying each draw of incidence by the selected set of ratios. We selected
incidence adjustments only for countries with a cumulative number of HIV deaths greater
than 5000 to avoid exaggerated stochastic variation in the ratios. We then derived estimates
of mortality by running the adjusted incidence curves back through Spectrum. By using
random draws across these countries, the average correction and uncertainty in this
correction is propagated into the corrections for these countries with little or no data.
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Concentrated epidemics with no high-risk group analysis and no cause of
death data—For 13 countries (Andorra, United Arab Emirates, Iraq, Federated States of
Micronesia, Libya, Marshall Islands, State of Palestine, Solomon Islands, Timor-Leste,
Vanuatu, Samoa, Tonga, and North Korea) no analysis of high-risk groups has been
undertaken and no cause of death data are available. For these countries, we picked regional
or neighbouring countries to approximate the death rate. We used these approximate death
rates to fit a Spectrum model. In all these cases, the number of estimated deaths was less
than 250 per year.
Comparisons to prevalence survey data—As a form of empirical validation, we
compared our final estimated prevalence with national population-based surveys collected
through the Demographic and Health Surveys, AIDS Indicator Surveys, the 2005–2006
Indian National Family Health Survey, and the 2012 South African National HIV
Prevalence, Incidence, and Behaviour Survey.78-80 In total, we extracted data from 46
surveys in 35 countries between 2001 and 2012. These surveys had response rates for HIV
testing ranging from 63% in male respondents in Malawi in 2004 to 98% for both sexes in
Rwanda in 2011; median response rate was 85%. These comparisons are made for adults
aged 15–49 by sex and 5-year age groups. We tested for significant differences in means
(p<0·05) for each estimate and compared the distribution of survey estimates to GBD and
UNAIDS via ordinary least squares (OLS) regression with robust standard errors to account
for heteroscedasticity.
HIV intervention counterfactual scenario—Spectrum uses as inputs the numbers
reported by governments of individuals receiving PMTCT, co-trimoxazole, and child and
adult ART. To help understand the role of interventions including ART, PMTCT, and co-
trimoxazole prophylaxis, we have rerun the final 1000 modified Spectrum models for each
country using a no intervention counterfactual scenario. We turn all HIV-related
interventions to zero including ART, PMTCT, and co-trimoxazole prophylaxis for all years.
We compared the number of deaths and person-years lived each year from the base case to
this counterfactual to assess the changes due to intervention. Using published results on
DAH for HIV, we computed the ratio of DAH to years of life saved.
Tuberculosis
For the GBD 2010, we estimated tuberculosis mortality and then estimated population
incidence through mixed effects regression as a function of tuberculosis mortality, case-
notifications, and an indicator variable for health system access used as a proxy for
completeness of registration. For GBD 2013, we have shifted to using all available data for
different outcomes and simultaneously estimating incidence, remission, excess mortality,
prevalence, and cause-specific mortality using the GBD Bayesian meta-regression
environment, DisMod-MR 2.0 (appendix p 11). There are four potential sources of
information to estimate national levels and trends for tuberculosis in a country: annual case
notifications, expert judgment on the case-detection rate, prevalence surveys, and cause of
death data. Additionally, to facilitate convergence of the meta-regression, estimated excess
mortality and remission rates have been used. The approach is predicated on the principle
that incidence, prevalence, and mortality might be measured imperfectly and that a statistical
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triangulation of all the sources for a country will provide a more robust assessment. Our
meta-regression analysis was done for all forms of tuberculosis. As a final step we estimated
incidence, prevalence, and death in individuals who are HIV-positive and those who are
HIV-negative. We explain in more detail the preparation of each of these sources.
Adjusted case notifications and incidence—Case definitions for tuberculosis since
1995 have been standardised by WHO and widely applied. Countries have varied however
in the completeness of reporting for younger age-groups and some countries have reported
only pulmonary smear-positive cases for selected years. We use the age and sex-specific
notifications in our analysis and impute the missing age-groups for three forms of
tuberculosis notifications (pulmonary smear-positive, pulmonary smear-negative, or extra-
pulmonary) in two steps. First, for each country-sex category with missing age-groups in
some years, we imputed the missing values by regressing the log of the case notification rate
on dummy variables for 5-year age-groups and random effects on year using all the data for
a country over the interval 1990–2013.
Second, we estimated the relation between all forms of tuberculosis and smear-positive
tuberculosis and the relation between all forms and bacteriologically positive tuberculosis.
Using country-years with complete notifications (all three forms), we used a compositional
analysis model to simultaneously estimate the fraction of cases due to all three forms as a
function of dummy variables for 5-year age-groups and sex and the smear-positive
tuberculosis rate. This regression was used to impute missing values for pulmonary smear-
negative and extra-pulmonary cases. Because of substantial variation in the diagnostic rates
for extrapulmonary tuberculosis and the potential for misclassification, we used the
predicted values for extrapulmonary cases for all countries from the regression.
At the country-level several smear-unknown and relapsed cases are recorded that are not
captured in the age-specific and sex-specific notifications. We used the relation between
these forms and pulmonary smear-positive cases in the country-level data to inflate the
adjusted age-specific and sex-specific pulmonary smear-positive notifications used in our
analysis. Case notifications, however, do not capture all true incidence cases in the
population. Case notifications can be incomplete because some cases are not diagnosed and
some diagnosed cases are not reported to the national tuberculosis programme. Population-
based incidence studies for tuberculosis based on active surveillance are rare and have not
been done at the national level.81 In the absence of direct measurement of true incidence, the
case detection rate must be approximated. Since 2008, WHO has been consulting with
national tuberculosis programme managers in 96 countries to collect expert opinion on the
case detection rate including some notion of subjective uncertainty.82 For the remaining
countries, case-detection estimates are based on the judgment of WHO staff. We divided
adjusted case notifications by the estimated case detection rate to generate the incidence
inputs used for DisMod-MR 2.0. We expanded the subjective uncertainty intervals reported
so they are at a minimum plus or minus 20% from the estimated values or for values less
than 20% we assume the standard error is half the midpoint estimate.
Tuberculosis prevalence surveys—Prevalence surveys have been periodically
undertaken in a few countries such as South Korea and China. WHO standardised the
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protocol and the Global Fund to Fight AIDS, Tuberculosis and Malaria has helped fund 24
surveys in 21 countries between 2002 and 2013 with 12 additional surveys in eight new
countries planned.82-84 Because the prevalence rates for tuberculosis are often
comparatively low (eg, 200 per 100 000 population), prevalence surveys need to be large to
provide breakdowns by age and sex. On the basis of the literature and country reports, we
have identified 27 national and 24 subnational prevalence surveys in 24 countries spanning
the time period 1985–2013. We have included in our analysis, surveys reporting on
pulmonary smear-positive tuberculosis and bacteriologically positive tuberculosis. We
included in the Bayesian meta-regression study level dummy variables for the different
measured outcomes with the reference category being bacteriologically positive. We
allowed for non-sampling variance for sub-national surveys to be larger which effectively
down-weighted their importance for the estimation in a given country. Because mortality
and incidence data are for all forms of tuberculosis, we adjusted prevalence surveys to
account for extra pulmonary cases using the same factors used in the adjustment of case
notification data.
Mortality—We used 2731 country-years of nationally representative vital registration data
and 166 site-years of verbal autopsy data to estimate tuberculosis mortality. Vital
registration data were adjusted for garbage coding following GBD algorithms74,85 and
misclassified HIV deaths described above. We modelled deaths by age and sex for
tuberculosis using the Cause of Death Ensemble modelling (CODEm) approach.76 CODEm
has been extensively used in global cause of death analyses.74 Using CODEm, we tested a
wide range of potential models and used out-of-sample predictive validity to select the best
individual models and the best ensemble of these models. The appendix (pp 152–186) shows
details on the application of CODEm to tuberculosis. We ran CODEm separately for male
and female individuals. The final ensemble models selected had a root-mean squared error
of the log of the age-specific death rate of 0·29 in-sample and 0·63 out-of-sample for males
and 0·70 in-sample and 1·05 out-of-sample for females. In the out-of-sample predictive
validity testing (cross-validation), the coverage of the 95% data prediction uncertainty
interval was 93% and 91% for males and females, respectively.
CODEm results are largely informed by ICD-coded data, which by definition exclude
tuberculosis mortality in HIV-positive individuals. The overall Bayesian model, however, is
for all forms of tuberculosis in HIV-negative and HIV-positive people because prevalence
data rarely distinguish HIV status. We estimated the fraction of HIV deaths due to
tuberculosis-HIV and added these to tuberculosis mortality in HIV-negative people. The
model for the fraction of tuberculosis-HIV mortality was based on 1022 country-years of
data when cause of death data for tuberculosis-HIV and HIV overall were available. We
estimated the relation between the logit-transformed fraction of HIV deaths due to
tuberculosis-HIV and the log-transformed tuberculosis death rate, a dummy variable for sex,
year, and country random effects. We used this regression to predict the fraction of HIV
deaths due to tuberculosis-HIV in all countries.
Remission and excess mortality estimates—To help inform the model, we generated
a Bayesian prior for remission by examining the ratio of incidence to prevalence in the
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country-years where prevalence surveys have been undertaken. We used a simple regression
with random effects to generate priors for countries with surveys and those without. Cause-
specific mortality estimates inform estimates of prevalence through excess mortality in
DisMod-MR 2.0. To provide the model with the range of age-specific and sex-specific
excess mortality hazards associated with tuberculosis we analysed historical data where we
had both tuberculosis mortality data and incidence data that were believed to be nearly
complete. For this analysis, we used the WHO case notifications from 1980 onwards with
the supplement of age-sex-specific case notifications back to the 1950s for Australia,
Canada, the UK, USA, Japan, and Germany. Case notification data were combined with
tuberculosis deaths recorded in the vital registration systems to generate 743 country-year
observations from 70 countries that could be used to inform our analysis. We estimated the
relation between incidence and mortality for each sex, by regressing the logit-transformed
ratio of incidence to mortality against age, lag-distributed income per head, and country
random effects. The addition of HIV prevalence off-ART to the regression gave inconsistent
coefficients between females and males and was not included in the final model. We
estimated the relation between incidence and prevalence as a function of lag-distributed
income per head with country random effects. We transformed predicted death to incidence
ratios and incidence to prevalence ratios into estimates of excess mortality and remission
using the mathematical relations between them (appendix p 7).
DisMod-MR 2.0—For each country we included in the DisMod-MR 2.0 estimation the
adjusted case notifications, prevalence survey data if available, estimated excess mortality
hazard by age and sex, estimated remission, and the tuberculosis-HIV adjusted cause-
specific mortality estimates from our CODEm model. DisMod-MR 2.0 provides internally
consistent estimates for 1990, 1995, 2000, 2005, 2010, and 2013 for 188 countries of
incidence, remission, excess mortality, prevalence, and cause-specific mortality using all
forms of data or priors in the estimation. Figure 5 shows the internally consistent fit for
Kenya in 2013. For intervening years, we interpolated rates.
Estimating tuberculosis incidence, prevalence, and death in individuals who
are HIV-positive—We used tuberculosis all-forms estimates from DisMod-MR 2.0 to
estimate incidence and prevalence in HIV-positive people using a relative risk approach. We
reviewed the literature using the search terms “incidence”, “risk ratio”, “HIV”,
“tuberculosis”, and “antiretroviral therapy” and used meta-regression to estimate a relative
risk of tuberculosis incidence in HIV-positive individuals in the absence of ARTs based on
seven studies86-92 of 8·7 (95% CI 5·9–11·7). Findings from previous studies show that the
relative risk of tuberculosis incidence is a function of CD4 count and ART; to parse out the
increasing risk ratios of tuberculosis by decreasing CD4 count and the decreasing risk ratio
on ART we used data from the Badri and colleagues’ study.93 The relative risks we
calculated from this analysis were 15·7 (10·6–21·1) for a CD4 cell count less than 200, 10·8
(7·3–14·5) for a cell count of 200–350, 3·2 (2·2–4·3) for a count greater than 350, and 1·7
(1·2–2·3) for the on-ART category. We computed population-attributable fractions for each
category using the outputs of Spectrum above. For prevalence, we assumed that each
category of incident tuberculosis cases in HIV-positive individuals has the same duration.
Tuberculosis-HIV mortality was estimated as described above.
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Murray and colleagues developed estimates of mortality and incidence for malaria for the
GBD 2010.74,94 They estimated malaria mortality using vital registration and verbal autopsy
data analysed using CODEm. Published community incidence studies were meta-analysed to
generate a model of incidence as a function of mortality, age, sex and region. We have
modified this method for the GBD 2013 update. Much debate emerged since the publication
of that analysis on the validity of verbal autopsy for adult malaria deaths.95-100 For the GBD
2013, we undertook a systematic review of the literature on the validity of verbal autopsy for
malaria. Our inclusion criteria were validation studies that used physician-certified verbal
autopsies, reported both sensitivity and specificity for malaria, and had hospital diagnosis as
the gold standard. However, the quality of the gold standards used in these studies was
variable, and in some of them malaria cases were not confirmed with a blood smear or did
not use a case definition with a threshold of parasitaemia. We identified seven studies.101-107
We first tested in a meta-regression if there was any statistically significant difference
between studies with and without parasitaemia confirmation and identified none. We meta-
analysed these studies to estimate sensitivity and specificity, separately for children and
adults. Forest plots for adult and children are shown in figure 6. As a sensitivity analysis, we
used this correction but it leads to substantially larger numbers of estimated deaths in adults
from malaria (appendix p 21). We have chosen not to correct the data for the main results of
this paper because it would adjust deaths in adults upwards which is contrary to expert
opinion in the literature.
In view of the fact that we have not applied the sensitivity and specificity corrections, we
have instead modified the redistribution of garbage codes such as fever of unknown origin
or ill-defined deaths, so that we do not redistribute garbage codes to malaria in adults. We
have also updated all the times-series covariates tested in the models: rainfall, health-system
access, antimalarial drug resistance weighted by drug use, ITN coverage, indoor residual
spraying coverage, income per head, and educational attainment. We have also included in
the model the 2010 P falciparum parasite rate (PfPR) map from the Malaria Atlas
Project.108 A coherent analysis of PfPR overtime is underway but was not available for this
analysis (see the appendix pp 223–40 for details on the CODEm model analysis). As in the
Murray and colleagues study, we developed separate models for sub-Saharan Africa and
outside of Africa (with the exception of South Africa, which was modelled with countries
outside of Africa, given the low malaria endemicity), age under 5 years and 5 years or
higher, and males and females.
For countries that have only or mainly Plasmodium vivax transmission we used the number
of deaths by year and age from vital registration data as a simple predictor of malaria
mortality using a negative binomial regression model.
We estimated malaria cases separately for three sets of countries, which were divided on the
basis of the availability and quality of malaria incidence data (see appendix pp 241–42 for
the list of countries). The first group contained countries with unavailable or unreliable
malaria case reporting systems. We estimated malaria incidence in these countries using a
mortality-incidence model, in which we predicted malaria incidence by regressing the log-
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transformed study-level incidence on the log-transformed malaria mortality rate, age-group
indicators, a sub-Saharan Africa indicator, an indicator distinguishing active versus passive
case detection (set to active when generating predictions), and the ratio of the site-specific
PfPR to national PfPR (from MAP 2010; set to the value 1 when generating predictions so
that the estimates are nationally representative). In this model, the incidence data came from
available studies and the mortality data came from our CODEm analysis. The second group
included countries for which there were incomplete administrative data, for which we
predicted malaria incidence by regressing incidence data from the World Malaria Report
2013 on national-level PfPR. We corrected for underreporting using a composite indicator
for health system access as a proxy. The third group contained countries with complete and
reliable administrative case reports, for which we used reported numbers as published in the
World Malaria Report.
CoDCorrect algorithm
As with all causes of death analysed for the GBD, we require that the sum of each individual
cause of death for a country, age, sex, and year equals the estimate of all-cause mortality.
The CoDCorrect algorithm rescales the sum of causes at the individual draw level. The
effect of this simple algorithm is to change causes that have larger uncertainty intervals if
there is a mismatch between the sum of cause-specific mortality and all-cause mortality. To
preserve the relations between incidence, prevalence, and death that come from the
Spectrum analysis, the entire epidemic curve for HIV is scaled in CoDCorrect.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The authors had access to the data in the study and
the final responsibility to submit the paper for publication.
Results
Figure 7 shows the estimated trend in global numbers of incident cases, people living with
HIV (prevalence), and deaths from HIV. Global HIV incidence peaked in 1997 with 2·8
million (95% uncertainty intervals 2·7 to 3·1) new infections and has since decreased at
2·7% (2·0 to 3·1) per year. From 1997 to 2005, incidence decreased at 3·8% (3·0 to 4·6) per
year and from 2005 to 2013 at 1·6% (0·6 to 2·4) per year. New infections in children
decreased from 340 000 (323 000 to 363 000) in 2000 to 134 000 (123 000 to 152 000) in
2013 at an annualised rate of change (ARC) of −7·2% (−7·8 to −6·4%), while new infections
in adults decreased from 2·3 million (2·1 million to 2·4 million) to 1·7 million (1·6 million to
2·0 million), falling at 2·4% (1·6 to 3·0) per year, on average, during this period. Annual
incidence estimated by UNAIDS is uniformly higher in the years shown and shows a
sharper rate of decrease. Prevalence of individuals infected with HIV has steadily risen to
29·2 million (28·1 million to 31·7 million) in 2013 rising more rapidly from 1990 until about
2000 at an annual rate of change of 10·6% (10·1 to 11·3), and increasing at 1·2% (0·9 to 1·4)
per year since (figure 7). Compared with UNAIDS’s estimations, our estimation for 2012
suggest 6·6 million fewer individuals living with HIV. 32·0% of this difference is in sub-
Saharan Africa and 68·0% is elsewhere. Figure 7 shows trends for HIV deaths compared
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with UNAIDS estimations, with a peak mortality of 1·7 million (1·6 million to 1·9 million)
in 2005. Annual mortality has subsequently fallen to 1·3 million (1·3 million to 1·5 million)
in 2013, an ARC of −3·1% (−4·0 to 2·2). While the time trend of mortality estimated by
UNAIDS is similar to ours, the estimated number of deaths is substantially greater. At the
peak of the epidemic in 2005, our revised assessment of the HIV epidemic suggests 635 000
fewer deaths than UNAIDS’s estimates, although the difference (240 000) narrows
substantially by 2012, the last year available from UNAIDS. For the interval 2005–12, the
UNAIDS ARC for death numbers was −5·0% (−5·6 to −4·5), reflecting the lower assumed
death rates on ART in the UNAIDS version of Spectrum.
New HIV infections are concentrated in young adults and to a much lesser extent, in
children under 5 years of age (figure 8); 4·1% (3·8 to 4·5) of new infections occur in
idividuals older than 60 years. New cases in 2013 occurred equally in both sexes. However,
there are more infections in women than men at ages 15–24 years. Incidence in children, and
in older adults, is similar for both sexes. Showing a mean survival time of more than 10
years in most countries and age-groups, the age pattern of deaths peaks in women at ages
35–39 years and in men at 40–44 years (figure 8). More deaths are in male individuals
(53·9% [51·9 to 56·1]) than in female individuals. The proportion of deaths that occur
beyond age 60 years (6·8% [6·2 to 7·4]) is larger than the proportion of incident cases that
occur beyond age 60 years (4·1% [3·8 to 4·5]).
Table 2 shows the ARCs for 1990–2000 and 2000–13 for incidence, prevalence, and death
for the 21 GBD regions and the world. ARCs between two fixed time periods need to be
interpreted bearing in mind that measures of the HIV epidemic such as incidence and death
will have peaked and decreased in particular countries at different times during the interval.
Nevertheless, our findings show the accelerated progress in most of the world’s regions. The
only regions with a reversal in the ARC such that incidence was decreasing but in the later
period is increasing or stagnating are southeast Asia, high-income North America, western
Europe, Australasia, and Tropical Latin America. The reversal in southeast Asia can be
explained by the large decrease in the 1990s achieved by a successful campaign to reduce
infection through commercial sex encounters in Thailand, the country in the region with the
largest epidemic. The reversal of incidence trends in North America might show a wearing
off of the effect of public health measures to reduce the risk of transmission in men who
have sex with men.
Age-standardised HIV incidence rates per 100 000 population (figure 9) in 2013 ranged
from less than 0·7 in a group of countries ringing the Eastern Mediterranean, parts of
northern and central Europe, and Mongolia, to more than 570 in South Africa, Lesotho, and
Swaziland. HIV infection follows distinct geographic patterns with continued high levels of
infection throughout eastern and southern Africa, with some exceptions. Rwanda, Burundi,
DR Congo, Congo, and Gabon all have incidence rates less than 120 per 100 000
population, lower than their neighbouring countries. Incidence rates vary widely in sub-
Saharan Africa, but are more homogenous across countries in Asia as well as North and
South America. Important exceptions to these patterns include incidence rates above 15 per
100 000 population in many Caribbean countries. Incidence rates are notably higher in
Portugal and Ukraine, as well as Russia and some Central Asian republics. Figure 9 shows
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prevalence rates in countries in 2013. Geographical patterns are similar to incidence,
although some differences are noteworthy. Prevalence levels are highest in Botswana,
Lesotho, and Swaziland (above 12 000 per 100 000 population). There is substantial
variation within sub-Saharan Africa; prevalence rates in Botswana, for example, are 15
times higher than in the DR Congo and 40 times higher than in Niger. In southeast Asia,
prevalence is substantially higher in Thailand and Papua New Guinea. Prevalence rates are
comparatively high in parts of Europe and central Asia (Portugal, Spain, Ukraine, Russia,
and Kazakhstan) and in Latin America and the Caribbean (Panama, Honduras, Belize,
Guatemala, Guyana, Suriname, Haiti, Dominican Republic, Jamaica, and Bahamas)
prevalence levels exceed 220 per 100 000 population. Comparison of incidence and
prevalence in figure 9 draws attention to some differences for countries in their comparative
ranking, such as for Sweden and Australia. Cross-national variations in HIV mortality rates
per 100 000 population, largely mirror the pattern reported for prevalence, varying from less
than 0·2 in northern and central Europe and the Eastern Mediterranean, to more than 520 in
southern Africa, a roughly 2500-fold difference (figure 10). Table 3 shows more detail on
the estimated number of new infections and deaths in 2013 for both sexes, individually and
combined, for 188 countries, along with ARCs in age-standardised incidence and death rates
for both sexes combined.
By comparing the estimated number of person-years lived in a no-intervention scenario with
actual estimates, we can compute the years of life saved through ART, PMTCT, and co-
trimoxazole prophylaxis. Figure 11 shows cumulative years of life saved by GBD region as
a result of these interventions during three phases of scale-up. From 1990 to 2003, 1·5
million years of life (1·2 million to 1·9 million) were saved, of which only 22·7% (14·2 to
32·1) were in populations living in developing countries, largely in Brazil. The number of
years of life saved increased substantially in the period 2004 to 2008 to 3·9 million (3·2
million to 4·7 million), and the share in populations in developing countries increased to
52·6% (44·1 to 62·2). Between 2009 and 2013, the number of life-years saved was 13·7
million (11·8 million to 15·7 million). A much greater share (40·8% [33·8 to 47·6]) of these
life-years saved were in eastern and southern sub-Saharan Africa, and a further 12·1% (9·0
to 15·7) in western sub-Saharan Africa. Other regions to benefit substantially from HIV
interventions include high-income North America, western Europe, and south Asia. The
number of years of life saved continues to grow rapidly due both to the continued expansion
of ART and the cumulative effect of infections prevented in children. By 2013, the global
cumulative number of years of life saved was 19·1 million (16·6 million to 21·5 million);
14·2% (12·4 to 16·2) at ages younger than 15 years, 49·7% (45·8 to 53·4) at age 15–49 years,
and 36·1% (32·7 to 39·5) at 50 years of age or older.
Since 2000, cumulative DAH for HIV up through 2011 totals $51·6 billion, of which $32·7
billion can be traced to specific developing country programmes in 2011 US dollars.109
Comparison of the total amount invested in HIV prevention and treatment to the years of life
saved during 2000–11 yields in developing countries a ratio of $4498 per life-year saved.
The ratio of DAH for HIV to years of life saved varies widely from $2·38 in Uruguay per
life-year saved to $1·87 million in Mongolia per life-year saved.
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The scale-up of ART has been variable across countries. Because of the temporal dynamics
of the epidemic in different countries, comparisons of intervention scale-up are confounded
by the timing of incidence. Nevertheless, the appendix (p 22) shows a crude comparison of
years of life saved over the age of 15 years divided by prevalent cases in people older than
15 years in 2013. This ratio ranges from less than 0·07 in countries with minimal
intervention to more than 0·49 in many high-income countries. In developing countries,
Brazil stands out with a ratio of 0·37. In the next tier, with ratios between 0·28 and 0·35
includes many countries in Latin America and Botswana, Namibia, Thailand, Cambodia,
South Korea, and some countries in central Europe. In eastern and southern Africa, Ethiopia,
Rwanda, and Burundi we saw higher ratios than in many of their neighbouring countries.
Pronounced variation within regions points to the historical variation in the timing of the
epidemic response.
Figure 12 shows a comparison of our estimated prevalence for country-age-sex groups
against national population prevalence surveys. This comparison provides a rough check
that at the end of the modelling process our assessment remains consistent with population-
based prevalence measurements as well as being consistent with data for all-cause mortality.
In general, there is a strong correlation (0·96) of our country-age-sex estimates with survey
prevalence—UNAIDS prevalence is also correlated (0·96) with survey data. However, in
21% of cases, there is a statistically significant difference (19% for UNAIDS). The
coefficients obtained by regressing both GBD and UNAIDS estimates on survey estimates
showed that both methods tended to be slightly higher than the surveys; however, only the
UNAIDS coefficient was a statistically significantly larger than one: UNAIDS, 1·08 (1·03 to
1·13); GBD, 1·02 (0·98 to 1·06). Country-specific graphs comparing GBD, UNAIDS, and
survey prevalences by age and sex are shown in the appendix (p 24).
Figure 13 shows the temporal changes of tuberculosis incident case numbers, the number of
prevalent cases, and the number of deaths from 1990 to 2013. Total tuberculosis numbers
are shown as well as numbers for tuberculosis in individuals who are HIV-negative. The
number of incident cases for tuberculosis in individuals who are HIV-negative has increased
from 5·0 million (4·8 million to 5·1 million) in 1990 to 7·1 million (6·9 million to 7·3
million) in 2013—a 1·5% (1·4 to 1·6) annual change. Prevalence in 1990 and 2013 was 1·6
times higher than incidence, implying a duration of 20 months on average for a case.
Prevalence rates increased slightly between 1990 and 2000 (ARC 0·4% [0·2 to 0·6]) but
decreased by 1·3% (1·4 to 1·2) per year from 2000 to 2013. Deaths from tuberculosis in
individuals who are HIV-negative are decreasing at a faster rate, from 1·8 million (1·7
million to 1·9 million) in 1990 to 1·3 million (1·2 million to 1·4 million) in 2013—a −1·4%
(−1·9 to −1·0) annual change. Decreases in death numbers and increases in incidence
numbers implies that the case-fatality rate has been falling over the period; the ratio of
deaths to incidence overall went from 0·36 (0·33 to 0·39) in 1990 to 0·18 (0·16 to 0·20) in
2013—a −2·9% (−3·4 to −2·5) per year rate of change. Most global tuberculosis incidence
cases and deaths in individuals who are HIV-negative are in men and boys, 64·0% (63·6 to
64·3) for incidence and 64·7% (60·8 to 70·3) for mortality (figure 14). Although age-specific
rates rise with age up to 70 years, in view of the comparatively young age-structure of
countries with substantial burden of tuberculosis in individuals who are HIV-negative,
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83·2% (82·6 to 83·8) of cases and 58·8% (56·7 to 60·6) of deaths were in people younger
than 60 years in 2013.
Table 4 shows a summary at the global and regional level of the ARCs for age-standardised
rates of incidence, prevalence, and deaths for tuberculosis in individuals who are HIV-
negative (see the appendix p 203 for tuberculosis including HIV-positive individuals). At the
global level, age-standardised mortality rates decreased by 3·3% (4·1 to 2·6), whereas
incidence remained stable (0·0% [−0·2 to 0·2]) and prevalence rates increased by 0·4% (0·2
to 0·6) during the period 1990 to 2000. Global decreases continued in the period 2000 to
2013 for mortality (−3·7% [−4·4 to −3·0]) whereas incidence decreased by 0·6% (0·7 to 0·5)
and prevalence decreased by 1·3% (1·4 to 1·2). Across regions, in the period 2000 to 2013,
incidence rate ARCs in individuals who are HIV-negative ranged from 0·8% (0·6 to 1·0) in
Oceania to −3·3% (−3·6 to −3·1) in high-income North America. 16 of 21 regions had a
greater decrease (or at least a smaller increase) in the incidence rate from 2000 to 2013 than
for 1990 to 2000. Mortality rate decreases in HIV-negative individuals were greater in the
period 2000 to 2013 than the decreases in prevalence in all 21 regions. The global decline in
prevalence from 2000 to 2013 is largely accounted for by the large decreases in just two
regions: east and south Asia. In south Asia, which accounts for 34·8% (33·9 to 35·6) of
incident cases and 47·7% (43·5 to 51·8) of deaths in 2013, the ARCs for 2000 to 2013 were
−1·1% (−1·3 to −0·8) for incidence, −2·4% (−2·7 to −2·2) for prevalence, and −4·2% (−5·6 to
−2·9) for mortality. Accelerated decreases in prevalence, incidence and mortality occurred in
east Asia from 2000 to 2013: −3·2% (−3·4 to −2·9) for prevalence, −2·1% (−2·4 to −1·9) for
incidence, and −7·5% (−8·5 to −6·6) for mortality. The tuberculosis trend in eastern Europe
has reversed: in the 1990s, mortality, incidence, and prevalence rates were all increasing,
with ARCs of 8·3% (5·5 to 9·1), 1·3% (1·0 to 1·7), and 1·7% (1·4 to 2·0), respectively.
However, in the period 2000 to 2013 the trends for all three of these indicators have
improved, with ARCs of −4·8% (−7·6 to −3·9), −0·6% (−0·8 to −0·4), and −0·7% (−1·0 to
−0·5). Table 5 shows incidence and deaths by country in 2013 along with ARCs for age-
standardised rates.
Figure 15 shows maps of age-standardised incidence rates and death rates for tuberculosis in
individuals who are HIV-negative in 2013. Age-standardised incidence of tuberculosis in
individuals who are HIV-negative is more than 200 per 100 000 population in 24 countries
in sub-Saharan Africa as well as in North Korea, Timor-Leste, Cambodia, Laos, Philippines,
and Kiribati (figure 15). There are an additional 16 countries with rates of more than 150 per
100 000 population that include Bangladesh, Myanmar, India, Pakistan, Ethiopia, and
Malawi. Figure 15 also shows tuberculosis death rates in individuals who are HIV-negative
which are above 10 per 100 000 population in all countries in sub-Saharan Africa and
increase to more than 50 per 100 000 population in 40 countries. Among middle-income
countries outside of sub-Saharan Africa, Afghanistan, Indonesia, India, Myanmar, and the
Philippines stand out as countries with death rates higher than 50 per 100 000 population.
The highest age-standardised death rates in Latin America and the Caribbean are in Haiti
followed by Bolivia and Peru. Death rates per 100 000 population are highly variable in
north Africa and the Middle East, ranging from very low in Syria (0·5 [0·3 to 0·9]) and
Jordan (0·8 [0·6 to 1·0]) to high in Morocco [14·3 [11·2 to 17·5]) and Yemen (19·9 [11·5 to
41·5]) in 2013. Eastern Europe and central Asia stand out with death rates that are
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substantially higher than western or central Europe. China has lower rates of death than
eastern Europe and central Asia. Our findings are mostly consistent with the list of high-
burden countries used by WHO; however, our top 22 countries in terms of case numbers or
death numbers that are not on the WHO high-burden list include South Korea, North Korea,
and Madagascar for case numbers and Angola and Zambia for mortality. WHO high-burden
countries that did not make our top 22 list for case numbers include Afghanistan, Cambodia,
and Tanzania, and the WHO high-burden countries that did not make our top 22 list for
mortality include Brazil and Cambodia.
Trends in the annual number of new cases of malaria, and annual deaths from malaria, are
shown in figure 16 for the period since 1990. Global incidence seems to have peaked in
2003 at 232 million cases (143 million to 387 million) and has since fallen by about 29% to
165 million new cases (95 million to 284 million) in 2013. There is massive uncertainty
around these estimates: the 2013 estimate, for example, could be anywhere between 95
million and 284 million. The estimates of new malaria cases in the World Malaria Report
fall within the uncertainty intervals of the GBD estimates with a mean number of new cases
in 2012 of 207 million (135 million to 287 million). By contrast with incidence data, the
World Malaria Report estimates of malaria deaths are slightly lower (figure 16). There are
also some important differences in the timing of the peak and decline in malaria mortality.
Annual malaria deaths began to decline from a peak of 1·2 million (1·1 million to 1·4
million) in 2004 to about 855 000 (703 000 to 1 032 000) in 2013, having increased from
888 000 (793 000 to 993 000) in 1990. According to the World Malaria Report,110 malaria
caused about 627 000 deaths in 2012, having reached a peak of about 900 000 around the
turn of the century. The age-sex pattern of global malaria incident cases and deaths in 2013
is shown in figure 17. The largest number of cases is in people younger than 15 years.
Malaria deaths, by contrast, are concentrated in children younger than 5 years, although
malaria caused between 10 000 and 25 000 deaths in each 5-year age group beyond age 15
years, so that the cumulative fraction of malaria deaths in adults reaches 33·75%.
Globally, age-standardised malaria incidence and death rates were increasing in the period
1990–2000 (table 6), but many regions outside of sub-Saharan Africa and north Africa and
the Middle East had decreases in age-standardised incidence, death rates, or both. In the
period since 2000, all regions including sub-Saharan Africa had decreases in age-
standardised incidence and death rates. Incidence decreased by 38% (37 to 40) in central
Asia since 2000, a result of increased malaria elimination efforts in the region. Figure 18
shows the geographical distribution of the age-standardised incidence rate in 2013. The
geographical distribution of the age-standardised mortality rate (figure 18) shows a similar
pattern with the highest rates in Mozambique, Burkina Faso, Guinea-Bissau, Mali, Sierra
Leone, The Gambia, and Guinea. Rwanda stands out as having low rates compared with its
neighbouring countries. Outside of Africa, Yemen, India, Myanmar, and Papua New Guinea
have death rates higher than 7·5 per 100 000 population. In southeast Asia, Thailand and
Malaysia have achieved very low death rates. Table 7 shows incidence and death numbers
by country in 2013 along with ARCs for age-standardised rates. Four countries have over 5
million cases a year including India with over 60 million cases, Nigeria (30 million), DR
Congo (with 6 million), and Mozambique (6 million). Three countries—Nigeria, DR Congo,
and India—account for roughly 50% of all malaria deaths in 2013.
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HIV, tuberculosis, and malaria remain major health challenges in 2013. The mean age of
death differs substantially between them, at 15·3 years for malaria, 38·6 years for HIV, and
52·9 years for tuberculosis in HIV-negative individuals, which means that the burden in
terms of years of life lost varies across the diseases. Tuberculosis deaths have decreased
globally since 1990, and after 2000 incidence, prevalence, and death have all decreased.
HIV incidence peaked in 1997 and mortality peaked in 2005 with substantial declines since
the peak in each. Malaria incidence and mortality peaked and began declining in 2004 with
substantial drops in the number of child deaths in sub-Saharan Africa over the past 5 years.
There is substantial variation both in levels and trends for all three diseases across countries.
HIV and malaria incidence and death are concentrated in sub-Saharan Africa whereas
tuberculosis burden is more widespread but most pronounced in south and southeast Asia.
From our analysis of HIV data, our findings show that the HIV epidemic is smaller than
estimated by UNAIDS. Our global epidemic curve for mortality ranges was lower than
estimated by UNAIDS for every year; at the peak in 2005 our estimates are 27·0% lower and
in 2012 are 14·5% lower. Our estimates of global prevalence differ from UNAIDS’s by
17·1% in 2005 and 18·7% in 2012. The substantial differences in the number of deaths stem
from two key differences in these analyses. First, in the 125 concentrated epidemics with
some cause of death data for mortality due to HIV, our estimated mortality is 52·2% lower
in 2000 and 58·4% lower in 2012 than UNAIDS’s estimates. Our prevalence estimates are,
for example, 36·3% lower for Panama, 52·2% lower for Colombia, and 58·4% lower in
Russia. Second, in the large generalised epidemics, selecting epidemic curves that are
consistent with prevalence data, all-cause mortality, and available studies on survival with
and without ART shifted median survival up. For example, in southern Africa, median
survival off ART for the age-group 25–34 years increased from 10·5 years to 11·5 years.
Longer or shorter survival off ART in some countries could be explained by genetic
factors,111-115 co-factors such as the presence of other diseases like malaria,116-118
differential access to treatments for opportunistic infections, or other co-factors that have not
been described. These findings are important in terms of identifying the magnitude and
comparative burden of HIV. Table 8 outlines the differences between our HIV/AIDS
estimation strategy and that of UNAIDS.
Comparison of population-based surveys with our estimates of prevalence suggest
reasonable alignment and the regression analysis of estimated prevalence on measured
prevalence suggest there is not systematic tendency in our estimates to overestimate or under
estimate prevalence. However, much variation exists by age and sex with nearly one in five
of our age-sex specific prevalence estimates statistically different than the survey
prevalences. Several potential explanations for this variation exist. Our assumptions about
the relative incidence pattern by country might not be true at the local level. Differential
non-response in the surveys by age and sex is also a potential factor. The adjustments made
through the demographic matching and CoDCorrect algorithm could contribute to the
differences. More analysis on a country-by-country basis will be helpful in exploring these
issues in future research.
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Revisions of the global epidemiology of HIV of this magnitude—in view of the weakness of
direct measurement of incidence and death—should not be surprising. As prevalence
surveys became more widely available, UNAIDS revised downward their global prevalence
estimates by 18% in 2007 and their global mortality estimates by nearly 24%.119 Taking into
account more data for survival on and off ART and incorporating all-cause mortality data
has led to revisions of a similar magnitude. Our revisions also suggests that there is greater
uncertainty for incidence, prevalence, and death than previously estimated. Irrespective of
the specific estimates generated from imperfect data, however, our assessment of prevalence
continues to point to the very large and steadily growing numbers of infected individuals,
many of whom are in need of antiretroviral therapy. Great progress has been achieved
reducing infections in children (62·4% reduction since the incidence peak in 2002) due to
the scale-up of interventions. The continued 1·7 million new infections per year in adults,
down 32·7% from the peak of the epidemic at the global scale, however, is a stark reminder
of the continuing epidemic.
A key finding that confirms many local, regional, and global studies120-125 is that
interventions, especially ART, PMTCT, and co-trimoxazole, have had a profound effect.
Cumulatively, 19·1 million years of life have been saved since 1996, 5·7 million in
developed countries and 13·4 million in developing countries, where the ratio of DAH to
years of life saved is less than $4500 for the average of the period 2000–11. In view of the
very rapid increase in years of life saved in 2012 and 2013, the ratio for the period 2000–13
when DAH figures are available will probably be much lower. The scale-up, number of lives
saved, and comparatively low price per year of life saved is one of the major achievements
in global health in the past decade. Many groups—local, national, and global—deserve
credit for this accomplishment. DAH does not count national contributions to the cost of
HIV programmes; real variation in the ratio of the total cost per year of life saved is
probably much smaller because many middle-income countries receive little DAH and fund
most HIV interventions from their own resources. Micro-economic studies of the cost per
years of life saved have also reported wide variation across locations.126-128 We would
expect, given investments in initial programme start-up including capital equipment
investments, that the ratio of DAH to life-years saved will decrease over time. With
prevalence growing 5·8% per year over the past 5 years, the need to learn from more
efficient programmes is paramount. Our analysis of survival on ART shows wide variation
in programme outcomes within sub-Saharan Africa. Counterfactual analysis of what might
happen if all programmes achieved the levels of mortality seen in the programmes with the
best outcomes or even what would happen if high-income country on-ART death rates were
achieved would help shed further light on the importance of quality improvement for future
HIV death reductions. Improving cost-effectiveness of ART programmes will require a
process of continuously documenting costs, outcomes, and efficiency along with a
mechanism for shared learning across programmes on improving quality. HIV infected
intravenous drug users have not benefited as much from treatment as those infected through
sexual transmission. Regions with an ongoing increase in mortality from HIV in the 2000–
13 period are high-income Asia Pacific, central and eastern Asia, eastern and central Europe,
north Africa and the Middle East, Oceania, and southern and western sub-Saharan. In a
number of these regions large proportions of HIV cases are in intravenous drug users for
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whom countries might be less inclined to provide treatment services. Even in countries with
a greater emphasis on harm-reduction strategies, drug users might still be a more difficult
group for health services to reach.129
Age-standardised tuberculosis mortality rates including tuberculosis in HIV-positive
individuals at the global level changed at −2·8% (−3·6 to −2·2) per year from 1990 to 2000
and around a percentage point faster from 2000 to 2013 (−3·7% [−4·4 to −3·0%]) per year.
When examining tuberculosis mortality in individuals who are HIV-negative, the
acceleration was smaller, from −3·3 (−4·1 to −2·6) to −3·7% (−4·4 to −3·0) change per year
but still statistically significant. There has been comparatively little decrease in the global
age-standardised tuberculosis incidence rates in HIV-negative individuals although some
regions such as south Asia and east Asia have seen accelerated declines since 2000.
Prevalence has decreased much faster than incidence, which is consistent with earlier and
more effective treatment-shortening durations. In addition to shorter duration, the death to
incidence ratio changed from 0·36 in 1990 to 0·18 in 2013, also a likely consequence of
treatment. There has been much regional and country variation in progress on tuberculosis
with the ARC for mortality ranging from −10·3% to 2·5% from 1990 to 2013 and the ARC
for incidence ranging from −3·3% to 2·5% over the same period. This variation implies that
more rapid progress is possible at the global scale if lessons can be learned from countries
with more rapid achievement. Since 2000, as for HIV and malaria, global progress in terms
of prevalence and mortality has accelerated. We are unable to compute the extra years of life
saved for tuberculosis as we can for HIV; but the comparatively small DAH for tuberculosis
over the period 2000–11 ($8·3 billion) has been associated over this time period with greater
reductions in incidence, prevalence, and death rates. Tuberculosis is different from HIV and
malaria in that the rising incidence and death rates with age mean that demographic ageing
of the world’s population in the absence of other changes will naturally lead to higher
numbers of cases and deaths. Demographic changes in essence slow the progress of
tuberculosis control; a factor that should be built into considerations of funding and
programme strategy. The established links between alcohol, diabetes, tobacco smoking and
tuberculosis also mean that trends in these risk factors can modulate trends in
tuberculosis.131-133 In this analysis, we have not separately examined the incidence,
prevalence, and mortality related to multi-drug resistant tuberculosis (MDR-TB). There are
concerns that even in places with substantial decreases in tuberculosis incidence, prevalence,
and death such as in China, MDR-TB might be a substantial challenge.82,133-136 Modelling
studies have shown that under specific circumstances MDR-TB could reverse important
gains made in combatting tuberculosis.82,136,137 Future revisions of the burden of disease
should examine more carefully the evidence on the levels and trends in MDR-TB.
Our results for tuberculosis differ from WHO estimates in some important ways. In general,
we estimate higher mortality, lower prevalence and incidence, and a smaller fraction of
tuberculosis related to HIV. Our estimates of prevalence are driven by the available
prevalence surveys and are not back calculated from incidence. Our incidence estimates start
with case-notifications corrected for missing age-groups and case types such as smear-
negative pulmonary or extrapulmonary and expert judgment of the case-detection rate. For
some countries, with implausibly large numbers of smear-negative and extra-pulmonary
cases notified in individuals younger than 15 years, we have excluded these data from the
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analysis. However, the Bayesian meta-regression identifies a solution for incidence that is
consistent with prevalence data and estimates of cause-specific mortality. Because this
analysis is undertaken using age-specific and sex-specific rates, it also takes into account the
changing relations between incidence, prevalence, remission, excess mortality, and cause-
specific mortality with age and sex. Because true incidence in any country is not known, our
estimates as well as WHO’s depend on expert judgment on the case-detection rate.
Systematic bias in the estimated case-detection rate, particularly for earlier time periods, will
affect not only the volume of estimated tuberculosis cases but also time trends. India
accounts for 27·1% (26·3 to 27·9) of global incident cases in 2013; systematic errors in the
estimated incidence in India in the 1990s would have a profound effect on global trends.
Perhaps more importantly, our assessment of global trends for death are similar to WHO but
differ for prevalence and somewhat for incidence. Because total age-sex-specific case
notifications reported to WHO for smear-positive pulmonary tuberculosis have continued to
increase—by 1·1 million in 2000, 2·3 million in 2005, and 2·5 million in 2012—differences
in time trends stem from assumptions about the case-detection rate and, in our study, the
incorporation of information from prevalence surveys and all-cause mortality. Table 9
outlines the differences between our tuberculosis estimation strategy and that of WHO.
Malaria burden rose steadily until 2004 and has since decreased. The Global Fund,
President’s Malaria Initiative, and other bilateral and private initiatives have spent $11·3
billion in DAH from 2000 to 2011. The hypothesis that global action has been an important
factor in these declines is highly plausible.6,110,138-141 The decline in our assessment is
driven by the statistical model fitted to the available but sparse verbal autopsy data. Key
independent variables in the model that drive this estimated decline are resistance for first-
line agents and ITN coverage. Noor and colleagues’142 assessment of trends in PfPR from
2000 to 2010 indicate that some countries such as Malawi, Zambia, or DR Congo have had
substantial scale-up of ITNs with minimal reduction or increases in PfPR. Explanations for
the mismatch between ITN scale-up and changes in PfPR could lie in the estimation of any
of PfPR, ITNs, or local factors that affect who actually receives and uses ITNs, or it could
be a function of other factors—eg, climatic changes over this period. There could also be
important threshold or saturation effects for ITNs on PfPR. While the substantial decline in
child mortality in the past 5 years is welcome news, understanding the relative role of
artemisin in combination treatment scale-up and vector control is challenging and might
vary by country. The variability in the relation between ITNs and PfPR at the national level
emphasises the risks of simply assuming that ITN scale-up at the national level will yield the
percentage reduction in child deaths seen in the randomised trials; a strategy used by Child
Health Epidemiology Reference Group (CHERG) in their child mortality estimates. It is also
important to note that the CHERG models did not include a first-line drug resistance as a
covariate. Our findings show this to be an important predictor in the Africa models in
particular and a key driver of the temporal trend noted in this region. Table 10 outlines the
differences between our malaria estimation strategy and that of WHO.
MDG6 brought global attention to these three diseases, ushering in an unprecedented focus
on specific diseases in the broader development agenda. Despite many who questioned the
wisdom of a focus on specific diseases, there has been accelerated progress on HIV, malaria,
and tuberculosis since 2000. In the case of HIV, our estimation strategy allows for direct
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quantification of years of life saved, which have been substantial. For tuberculosis and
malaria, we see accelerated reductions in deaths and cases compared with the decade before
the Millennium Declaration. Rigorously assigning causality to these accelerations to the
global collective action catalysed by the Millennium Declaration is beyond the scope of this
paper and likely impossible in view of the data limitations. Nevertheless, as governments
and the global community debate the nature, scope, and utility of setting new global targets
post-2015, these findings should be taken into consideration.
Our comparative analysis of these three diseases shows pronounced differences in data gaps
and measurement challenges. Antenatal clinic serosurveillance and population surveys in
generalised epidemics have been a powerful tool for tracking evolution of the HIV epidemic
with real data collected on an annual basis. Cause of death data in many countries with
concentrated epidemics also provide a timely way to examine the effect of HIV. But,
national data for the outcome of ART is weak. Measures such as retention in care and loss to
follow-up are often incomplete and difficult to compare across facilities, programmes, and
countries. UNAIDS and our modelling do not routinely use national data for treatment
outcomes and depend on cohort or published studies. In view of the huge effect of ART on
death and prevalence, more accurate and continuous monitoring of ART outcomes and costs
must be a high priority. By contrast with HIV, tuberculosis treatment outcomes are highly
standardised and reported to WHO at least through the end of treatment. However, real-time
data for the time-trends of tuberculosis is hard to come by. Case notifications can only be
interpreted by resorting to expert opinion on the case detection rate, and prevalence surveys
are infrequent and require large sample sizes. A system analogous to the antenatal clinic
serosurveillance for tuberculosis would be possible if new diagnostics emerge that can
quantitatively assess load of bacilli in an infected individual. Pending such a technological
advance, more frequent prevalence surveys and perhaps capture-recapture studies82 are the
only direct measurement available to track evolution of the epidemic. In our study, ARC for
incidence and prevalence 2000 to 2013 is correlated (0·93). Information about malaria
clinical cases and deaths is much weaker than for HIV or tuberculosis. Case reports are very
incomplete. Most deaths occur in places without vital registration systems. Verbal autopsy is
widely believed to exaggerate malaria deaths, especially in adults,143-145 in view of the
tendency to overdiagnose malaria in African hospital settings;146-149 our systematic review
of validation studies, though, shows low sensitivity (33%) and low specificity (93%). Bias is
a function of both sensitivity and specificity. If these validation studies that are published are
correct we might be underestimating and not overestimating malaria deaths in adults and
children in areas with substantial malaria and the reverse in areas with little malaria. The
only comparatively easy-to-measure outcome related to malaria is the P falciparum parasite
rate. Local surveys have been usefully collated and analysed by Noor and colleagues and the
Malaria Atlas Project.142 These data provide hard evidence on the trends in a measurable
outcome; the challenge is that there is a loose relation in the available data between PfPR
and incidence or mortality. In view of how important malaria is, the state of monitoring
systems for malaria burden is poor. Repeated verbal autopsy studies combined with
carefully designed validation studies would be helpful. Better data for the incidence of
clinical episodes confirmed with rapid diagnostic tests and how it varies as a function of the
PfPR would improve incidence estimation.
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Findings for these three diseases draw attention to the difference between ICD-assigned
underlying cause of death and the total mortality attributable to a disease including pathways
through which a disease aggravates other disorders. ICD rules treat disorders—not just these
three diseases—in this regard in substantially different ways. All deaths directly related to
pregnancy and childbirth and any deaths aggravated by pregnancy are counted as maternal
deaths. For HIV, all deaths in individuals who are HIV-positive are assigned to HIV unless
they are due to completely incidental causes such as a road traffic injury. Following this
convention, tuberculosis deaths in HIV-positive people are assigned to HIV not tuberculosis.
In the case of malaria, there has long been the recognition that malaria might increase the
risk of death in children and adults from other causes such as septicaemia or chronic kidney
disease.150-152 Early studies after the country-by-country elimination or rapid control of
malaria documented rapid changes in deaths from pneumonia and chronic kidney
disease,153,154 suggesting the full effects of malaria on mortality are greater than the ICD-
coded malaria deaths. The ITN randomised controlled trials based on verbal autopsy
documented that about half of the declines in under-5 mortality were in causes other than
malaria assigned through a verbal autopsy.155,156 Our understanding of the magnitude of
each disease is affected by the at-times arbitrary rules governing assigning causes of death.
There are two important general observations from our analysis of HIV compared with prior
analyses that might be relevant to other diseases. First, we saw that concentrated epidemics
have been systematically over estimated by a factor on average of more than two.
Overestimation is most likely related to a tendency to overestimate the size of high-risk
groups for which little information exists. Why would expert judgment be, on average, so
wrong? The disconnect in many countries between expert judgment and the results emerging
from the analysis of cause of death data should caution researchers in the future from too
much dependence on expert judgment in descriptive epidemiology. Second, we saw a
systematic under-estimation of uncertainty in many countries in the UNAIDS analysis. Their
assessment for South Africa, for example, had for 2010 an uncertainty interval with a
coefficient of variation of 0·03. Our assessment before matching on all-cause mortality had a
coefficient of variation about six times higher (0·19) in the same year. There is a general
tendency, we believe, in many modelling efforts to underestimate uncertainty when arbitrary
assumptions about parameters are made. For example, the default assumptions for
uncertainty in the UNAIDS Spectrum model is a coefficient of variation 0·05 for mortality
on and off ART. We find from our empirical analysis coefficients of variation that range
from 0·44 (in the age group 15–24 years and CD4 count greater than 500) to 1·00 (in people
aged 45 years or older and a CD4 count greater than 500). In other words, uncertainty in
these parameters seems to have been underestimated, with the real value approximately ten
times larger. This is not a critique of the UNAIDS Spectrum modelling effort, rather a
reminder that statistical analysis of parameter uncertainty often shows that we know much
less than we think.
Our analysis of HIV in India based on the 2005–06 National Family Health Survey and
antenatal clinic serosurveillance suggests that in 2002 there were 287 000 (199 000 to 377
000) deaths. Cause of death data, however, are available from several sources all pointing to
substantially lower numbers of deaths than UNAIDS high-risk group analysis. Using data
for 2001–03, investigators in the Million Death Study reported an estimated 59 000–140 000
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deaths in 2004. The urban Medical Certification of Causes of Death system recorded a peak
age-standardised death rate in 6·3 per 100 000 population, which is equivalent at the national
level to 57 000 deaths. We did not use these sources in our assessment; the substantial
mismatch between our estimates draws attention to the need for improved understanding of
causes of death in India.
Some global health efforts to develop robust estimates of the burden of disease sometimes
end up using both empirical measurement on incidence, prevalence, and cause-specific
mortality plus coverage of interventions and assumed effectiveness of interventions. The
blending of real measurement of outcome and assumed mapping of interventions to outcome
is justified because recent scale-up of interventions might not be accounted for in the sparse
measurements that are available. We used the modified Spectrum model to map ART
coverage into likely changes in mortality from HIV. These findings are lent support in some
countries by measured declines in all-cause mortality or cause-specific mortality but in other
countries are based entirely on the presumed relation between intervention roll-out and
mortality. Many examples of such blending of data for outcome and intervention coverage
exist: CHERG estimates of decreases in child deaths due to ITNs and Hemophilus influenza
type B vaccine coverage are not based on any statistical relation but on the assumption that
interventions will yield the decreases seen in randomised trials. These are reasonable
assumptions but fundamental difference exist between observing the change in outcome as
opposed to assuming the outcome has changed; this difference is not immediately evident in
global health estimation efforts. It can yield circular analyses in which estimates are used by
other authors to assess impact. In general, in the GBD 2013, we have sought to use largely
empirical data and statistical associations seen in the data to make estimates. But for HIV in
particular, we have used the approach embodied in Spectrum.
This analysis of data for HIV, tuberculosis, and malaria has many limitations in view of the
ambition to track incidence, prevalence, and mortality for 188 countries from 1990 to 2013.
First, ART estimates for 2013 are highly preliminary. Countries have reported ART scale-up
through 2012 and provided estimates for 2013. Many of these estimates were aspirational
and we have used growth rates over the 5 years 2008–12 to adjust these 2013 estimates.
Second, we have not independently validated the country reports of ART scale-up. We have
added to the uncertainty by randomly varying ART scale-up by sampling a uniform
distribution from plus to minus 10% but this presumes that, on average, ART scale-up is not
exaggerated. Third, we have used 102 studies of ART outcomes to inform our assumptions
of death rates on ART. There was much variation across sites. More recent programmes
might be achieving better outcomes than previous studies have shown if there has been
shared learning across programmes. Available studies might also be biased towards better
outcomes through the publication bias; poor programmes are unlikely to seek to publish
their results. There was insufficient national data to use local information about each country
on ART programmes. Our estimates might be biased up or down for a given country
because local ART outcomes might be better or worse than the sub-Saharan Africa average.
Future rounds of estimation will be substantially improved by more robust ART treatment
outcome data obtained from nationally representative samples of patients on ART across a
wider range of countries. Fourth, we have sought to find epidemic curves for the major
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generalised epidemics that are both consistent with available prevalence data and all-cause
mortality data derived from sources such as vital registration or sibling histories in
household surveys. The process of matching all-cause mortality draws and Spectrum outputs
that are consistent also substantially reduces uncertainty. In view of the mismatch of these
data sources, we are probably underestimating uncertainty in these countries. Fifth, we have
not modified the UNAIDS assumptions for survival in children infected with HIV.
However, published studies from high-income countries pre-ART suggest much higher
survival.157 Our estimates of death in the age-groups 5–9 years and 10–14 years might
therefore be exaggerated. Sixth, our estimates of uncertainty for HIV could be
underestimated because some of our uncertainty ranges for parameter inputs have been
selected arbitrarily and true variation, for example, in age-sex patterns of incidence might be
larger. The idea that variations in age-sex patterns of incidence might be larger is lent
support by the number of age-sex-country-years in which our estimates of prevalence are
different to those available from national prevalence surveys. Seventh, on the basis of debate
over the burden of malaria in adults, we chose not to redistribute garbage code deaths onto
malaria in verbal autopsy studies in adults, which led to a reduction in the estimated number
of adult malaria deaths. Although this choice was informed by expert opinion, it was not
based on any direct data. Even without the redistribution of garbage codes, the percentage of
deaths occurring in adults in Africa is still high and has to be interpreted with caution in
view of the potential for misclassification bias in verbal autopsies. Alternatively, the choice
not to redistribute ill-defined codes onto malaria might bias our adult deaths downwards.
Eighth, Noor and colleagues have published PfPR for 2000 and 2010.142 A full time-series
of PfPR would be a useful covariate for modelling the burden of malaria. The Malaria Atlas
Project is working on such time-series analysis of PfPR and when it is finalised it would
strengthen the analysis of malaria trends. Ninth, our uncertainty intervals for malaria
incidence and mortality incorporate sampling uncertainty, non-sampling un certainty, and
model-specification uncertainty, but do not incorporate the uncertainty that can stem from
misclassification biases in verbal autopsy. Uncertainty is probably underestimated due to the
limitations of verbal autopsy for malaria in children and adults. Tenth, findings from other
studies in countries such as The Gambia suggest substantial decreases in malaria in these
settings; in our analysis of mortality, however, these types of studies have not been
used.158,159 Eleventh, our analysis of tuberculosis assumes that local expert judgment about
the case-detection rate is unbiased; this assumption, however, might be incorrect for
countries with higher or lower case-detection rates. Twelfth, our uncertainty intervals for
tuberculosis incidence and prevalence generated from DisMod-MR 2.0 are probably
underestimated. The intervals are narrow because we have extensive data inputs for
essentially all countries in the form of adjusted case-notifications and CODEm estimates of
all-cause mortality. Although each data point has substantial uncertainty, the meta-
regression produces narrow estimates of the predicted mean value for an age-sex-country-
year because of the extensive and often consistent data. These intervals do not capture the
potential for systematic error in some of the data-processing steps such as the use of the
expert-based case-detection rate. Despite these important limitations, the GBD approach has
many advantages, primarily because it is a comprehensive and clearly documented approach
to disease burden estimation that examines all the available data and invests substantial
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effort into standardisation of definitions, data adjustments, and modelling across all diseases
and injuries.
The focus of the global health community on action to reduce HIV/AIDS, tuberculosis, and
malaria, enshrined in MDG6, was not only appropriate in 2000 at the Millennium
Declaration, but is increasingly relevant now in view of the slow but important progress that
disease control strategies have yielded, particularly since 2005. Much remains to be done,
however: although evidence now exists that the implementation of known interventions is
beginning to have an effect, it is probably less than is widely believed, or hoped. But these
interventions are working, and need to be rapidly scaled up with more funding, more
emphasis on national health system strengthening in key affected countries to increase
access to them by the poor, and more targeted research to accelerate progress. What is also
clear from this analysis as we enter the final phase of the MDG era is how little we reliably
know in many countries to track progress. Rapidly reducing the massive uncertainty that
surrounds the measurement of these diseases, particularly malaria, will be essential if we are
to better monitor, and respond to, evidence about progress, or not, with their control.
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Figure 1. UNAIDS compartmental model for estimating mortality in HIV-positive individuals in
the absence of ART
ART=antiretroviral therapy.
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Figure 2. HIV relative survival after seroconversion for male and female individuals aged 25–34
years based on the analysis of 13 ART-naive cohort studies
Solid lines show means; shaded area shows 95% uncertainty intervals (uncertainty intervals
not available for UNAIDS data). ART=antiretroviral therapy.
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Figure 3. HIV deaths in Thailand (A) and Russia (B) by age in 2005 for both sexes combined
Data are for vital registration deaths assigned to HIV (red), deaths coded to garbage codes
redistributed to HIV (blue), and misclassified deaths reassigned to HIV (green). The height
of the bar is the final number of deaths in each age group.
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Figure 4. Vital registration inputs, and Spectrum and UNAIDS HIV mortality draws for
Panama
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Figure 5. Bayesian meta-regression estimates for tuberculosis prevalence (A), incidence (B),
remission (C), excess mortality (D), and cause-specific mortality (E) for male individuals in
Kenya, 2013
For each observation in black, the length of the horizontal bar refers to the age interval of
the observation and the length of the verticle bar refers to the uncertainty interval. To
stabilise estimates, all data from 2008 to 2013 are included.
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Figure 6. Meta-analysis of published validation studies of verbal autopsy for malaria in adults
(A) and children (B), both sexes combined
The solid lines show 95% uncertainty intervals (ui); the dotted lines show the point estimate
of the pooled estimate (the diamond). The age cutoff for children is <15 years.
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Figure 7. Global HIV incidence (A), prevalence (B), and mortality (C), 1990-2013, for all ages
and both sexes combined
Shaded areas are 95% uncertainty intervals.
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Figure 8. Global age-sex distribution of new HIV infections (A) and deaths (B) in 2013
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Figure 9. Age-standardised HIV incidence (A) and prevalence (B) in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
TLS=Timor-Leste.
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Figure 10. Age-standardised HIV mortality in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
TLS=Timor-Leste.
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Figure 11. Years of life saved (YLS) through prophylactic treatment by region in 1990–2003 (A),
2004–08 (B), and 2009–13 (C), both sexes
Treatment includes antiretroviral therapy, prevention of mother-to-child transmission, and
co-trimoxazole prophylaxis.
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Figure 12. Comparison of 43 national HIV prevalence survey results for people aged 15–49 to
prevalence estimates from the GBD 2013 and UNAIDS for the same year and age-group
Each point corresponds to an estimate for a particular country, survey year, sex, and 5-year
age group. The solid line indicates the line of equivalence.
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Figure 13. Global tuberculosis incidence (A), prevalence (B), and deaths (C), 1990-2013, for all
ages and both sexes combined
Shaded areas show 95% uncertainty intervals.
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Figure 14. Global age-sex distribution of tuberculosis incidence (A) and deaths (B) in HIV-
negative individuals in 2013
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Figure 15. Age-standardised tuberculosis incidence (A) and death rates (B) in HIV-negative
individuals in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
TLS=Timor-Leste.
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Figure 16. Global malaria incidence (A) and deaths (B), 1990–2013, for all ages and both sexes
combined
Shaded areas are 95% uncertainty intervals.
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Figure 17. Global age-sex distribution of malaria incidence (A) and deaths (B) in 2013
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Figure 18. Age-standardised malaria incidence (A) and death (B) rates in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
TLS=Timor-Leste.
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Table 1
HIV-specific mortality rates for adults aged 25–34 years on antiretroviral therapy in sub-
Saharan Africa, by time since initiation, sex, and initial CD4 count (per 100 person-years)
Women (time since initiation) Men (time since initiation)
0–6 months 7–12 months 13–24 months 0–6 months 7–12 months 13–24 months
<50 CD4 cells per μL 40·6 (20·4–71·5) 8·9 (6·0–13·4) 4·0 (2·7–5·7) 53·1 (26·5–93·5) 11·6 (7·9–17·5) 5·2 (3·6–7·5)
50–99 CD4 cells per μL 17·4 (12·2–25·0) 6·5 (5·0–8·4) 3·0 (2·3–3·9) 22·8 (16·2–32·4) 8·6 (6·5–11·2) 3·9 (3·0–5·1)
100–199 CD4 cells per μL 14·1 (10·4–18·4) 5·7 (4·4–7·2) 2·6 (2·0–3·3) 18·4 (13·6–24·2) 7·4 (5·8–9·5) 3·4 (2·6–4·3)
200–249 CD4 cells per μL 12·5 (8·9–16·6) 5·1 (3·8–6·5) 2·4 (1·8–3·1) 16·3 (11·6–21·7) 6·6 (4·9–8·6) 3·1 (2·3–4·0)
250–349 CD4 cells per μL 10·7 (7·0–14·8) 4·4 (3·0–6·0) 2·0 (1·4–2·7) 14·0 (9·3–19·4) 5·7 (3·9–7·8) 2·6 (1·8–3·6)
350–499 CD4 cells per μL 8·1 (4·7–12·0) 3·1 (1·8–4·8) 1·4 (0·7–2·2) 10·5 (6·0–15·8) 4·1 (2·4–6·2) 1·8 (1·0–2·8)
≥500 CD4 cells per μL 6·3 (0·9–11·0) 2·3 (0·1–4·4) 0·9 (0·0–2·0) 8·2 (1·2–14·7) 3·0 (0·1–5·7) 1·2 (0·0–2·6)
Data in parentheses are 95% uncertainty intervals.
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Table 2
Age-standardised HIV/AIDS incidence, prevalence, and mortality rates, and annualised
rates of change for both sexes for 21 Global Burden of Disease regions
Age-standardised rates in 2013 (per
100 000 population)
Annualised rate of change (%)
1990–2000 2000–2013
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Age-standardised rates in 2013 (per
100 000 population)
Annualised rate of change (%)
1990–2000 2000–2013
Incidence Prevalence Mortality Incidence Prevalence Mortality Incidence Prevalence Mortality





































































































































































































































Data in parentheses are 95% uncertainty intervals.
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Table 4
Age-standardised tuberculosis without HIV incidence, prevalence, and mortality rates
and annualised rates of change for both sexes for 21 Global Burden of Disease regions
Age-standardisedrates in 2013 (per
100000 population)
Annualised rate of change (%)
1990–2000 2000–2013
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Age-standardisedrates in 2013 (per
100000 population)
Annualised rate of change (%)
1990–2000 2000–2013
Incidence Prevalence Mortality Incidence Prevalence Mortality Incidence Prevalence Mortality

























































































































































































































Data in parentheses are 95% uncertainty intervals.
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Table 6
Age-standardised malaria incidence and mortality rates and annualised rates of change
for both sexes for 16 Global Burden of Disease regions
Age-standardisedrates in 2003
(per 100 000 population)
Annualised rate of change (%)
Incidence Mortality 1990–2000 2000–13
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Age-standardisedrates in 2003
(per 100 000 population)
Annualised rate of change (%)
Incidence Mortality 1990–2000 2000–13
Incidence Mortality Incidence Mortality

























Data in parentheses are 95% uncertainty intervals.
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Table 8
Comparison between Global Burden of Disease 2013 verses UNAIDS 2013 HIV estimates
GBD 2013 UNAIDS 201360,160
Incidence, prevalence, and mortality
Key data sources and
inputs
• Vital registration (VR) data
• UNAIDS’ 1000 Estimation and Projection
Package (EPP) incidence and prevalence curves
• GBD 2013 HIV-free life tables
• UNPOP World Population Prospects (WPP)
2012 population and fertility estimates
• Antiretroviral therapy (ART), prevention of
mother-to-child transmission (PMTCT), and
other intervention coverage data reported to
UNAIDS
• HIV mortality rates on-ART from systematic
literature review (102 studies)
• HIV mortality rates off-ART from systematic
literature review (13 cohort studies)
• UNAIDS assumptions for other spectrum HIV
inputs
• Population surveys of HIV prevalence
• Antenatal care (ANC) surveillance
• Surveillance data for high-risk groups
• UNPOP World Population Prospects
2010 population, fertility and HIV-free
mortality estimates
• ART, PMTCT, and other intervention
coverage data reported to UNAIDS by
countries; UNAIDS states these are
validated by UNAIDS, WHO, and
UNICEF but no method for validation is
provided
• Assumptions on the percent of the
population in high-risk groups for each
country with a concentrated epidemic;
UNAIDS states that estimates are
derived empirically, based on regional
values or expert consensus but provides
no detail by country on the empirical
basis for the assumptions
• UNAIDS assumptions for other
Spectrum HIV inputs based on a range of




• VR data adjusted for completeness
• VR data adjusted for garbage coding and
misclassification HIV deaths
• None
Modelling strategy All countries:
• Age-sex-CD4-specific estimates of HIV
mortality on-ART and off-ART based on meta-
regression of studies from literature reviews
• Spectrum recoded in open-source language
Python to facilitate uncertainty analysis
Generalised epidemics and populations with national
surveys:
• 46 countries
• EPP outputs (15-49 years, both sexes) for
generalised epidemics used as an input to
modified Spectrum
• EPP fit to national prevalence data for India,
Senegal, and Niger
• Spectrum (Python version) run with modified
death rates on and off ART, GBD HIV-free
mortality, and WPP 2012 population estimates;
intervention estimates for ART, PMTCT as
reported by UNAIDS
• Sampling uncertainty distributions for all input
parameters generate 10 000 year-age-sex
specific estimates of HIV mortality, incidence,
and prevalence
Generalised epidemics and countries with sufficient
HIV prevalence data:
• 41 countries
• EPP (one of three variants) used to
generate incidence and prevalence curves
for urban and rural or regional
breakdowns with survey and ANC
surveillance data; aggregation to
generate national curves for ages 15-49
years in both sexes combined. Fitting
parameters including start year of the
epidemic modified to eliminate
unrealistic fits from the statistical model.
Incidence adjusted downward by 92%
for the fraction of people on ART.
• EPP outputs with Spectrum inputs and
WPP 2010 demographic data to generate
year-age-sex specific estimates of HIV
mortality, incidence, and prevalence
• Selective modification of input
parameters including ART survival
based on country consultation process
Concentrated epidemics in populations greater than
250 000:
• 114 countries
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GBD 2013 UNAIDS 201360,160
• Selection of the 1000 epidemic curves that
minimize the gap between GBD 2013 all-cause
mortality estimates and Spectrum mortality
outputs
Concentrated epidemics with VR:
• 125 countries
• Space-time Gaussian Process Regression (ST-
GPR) on adjusted VR data to produce complete
time series of age-sex-specific mortality
• EPP outputs (15-49 years, both sexes) with
Spectrum inputs, GBD 2013 demographic data,
and updated on-ART and off-ART mortality
analysis to run Spectrum and generate 1000
year-age-sex specific estimates of HIV
mortality, incidence, and prevalence
• Adjusted incidence from Spectrum using the
ratio of ST-GPR modelled mortality to
Spectrum modelled mortality with six different
assumptions of the lag from year of infection to
year of death (10-15 years). This produced 6000
time series of incidence (15-49 years, both
sexes)
• Adjusted incidence with GBD HIV-free life
tables, WPP 2012 demographic data, and
updated on-ART and off-ART mortality
analysis to run Spectrum and generate 6000
year-age-sex specific estimates of HIV
mortality, incidence, and prevalence
• Select 1000 with the smallest root mean squared
error between model predictions of mortality
and the vital registration data
Concentrated without VR:
• 17 countries
• Extrapolation of incidence and prevalence for
countries where UNAIDS does not generate
estimates by randomly selecting draws from
countries in the region with estimates
• Regional average of all other Spectrum inputs
for countries where UNAIDS does not generate
estimates
• EPP outputs (15-49 years, both sexes) with
Spectrum inputs, GBD 2013 demographic data,
and updated on-ART and off-ART mortality
analysis to run Spectrum and generate 1000
age-sex specific estimates of HIV mortality,
incidence, and prevalence
• Random selection of 1000 ratios used in the
incidence adjustment process from countries
with relatively high prevalence
• Use selected ratios to adjust incidence in the
absence of ST-GPR results, producing 1000
adjusted incidence curves (15-49 years, both
sexes).
• Adjusted incidence with Spectrum inputs, GBD
2013 demographic data, and updated on-ART
and off-ART mortality analysis to run Spectrum
and generate 1000 year-age-sex specific
estimates of HIV mortality, incidence, and
prevalence
• EPP used to generate incidence and
prevalence curves for high-risk groups
using surveillance data for these
populations
• Aggregation to generate national curves
(15-49 years, both sexes) based on
assumptions about the fraction of the
population in each high-risk group
• EPP outputs with Spectrum progression
parameters, reported ART and PMTCT
coverage, and WPP 2010 demographic
data to generate year-age-sex specific
estimates of HIV mortality, incidence,
and prevalence
• For some countries with insufficient data
on prevalence in high-risk groups,
reported HIV diagnoses over time and
assumptions about the fraction diagnosed
used
• Selective modification of assumptions on
the percentage of the population in each
high-risk group and other Spectrum input
assumptions through country
consultation process
Countries with populations less than 250 000:
• No estimates constructed
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GBD 2013 UNAIDS 201360,160
Uncertainty • Use the 1000 EPP incidence curves consistent
with the available prevalence data
• Generated 1000 sets of CD4 progression and
CD4 specific mortality on and off ART sampled
from the meta-regression of published studies
• Sample a uniform distribution of -10% to +10%
of the mean value for all other Spectrum
parameters including numbers on ART and
PMTCT
• The sex ratio of incidence was sampled from a
uniform distribution of -20% to +20% of mean
value
• Major limitation is that uncertainty intervals for
many parameters are sampled from an arbitrary
uncertainty interval
• EPP likelihood estimation of incidence
reflects uncertainty in prevalence data
• Uncertainty in the percent of the
population in high-risk groups or urban
and rural breakdown not incorporated
• All uncertainty adjustments to non-EPP
inputs are arbitrary and small compared
with GBD
• Uncertainty propagated after point
estimates generated—coefficients of
variation for parameters arbitrarily
selected and only for selected variables
(eg, for adults ratio of fertility of HIV-
positive to HIV-negative women, ratio of
male to female incidence, average
number of years in each CD4 category,
HIV mortality without ART, HIV
mortality with ART)
• No uncertainty incorporated for CD4
progression overtime or distribution of
CD4 counts at seroconversion
GBD 2013 differences • Recoded Spectrum in the Python programing
language to enable the model to run more
efficiently and allow for full uncertainty
analysis
• Expanded uncertainty in Spectrum estimates of
mortality, incidence, and prevalence by
sampling distributions around most Spectrum
inputs
• Empirically estimated uncertainty for HIV
mortality on-ART and off-ART
• Used VR data when available to inform
estimates of mortality for concentrated
epidemics
• Identify epidemic curves and all-cause mortality
estimates in countries with large epidemics that
are most consistent with each other
• Sum of cause-specific mortality estimates for a
country-year-age-sex group must equal all-
cause mortality estimate at the draw level
(CoDCorrect algorithm)
N/A
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Table 9
Comparison between Global Burden of Disease 2013 verses WHO 2013 tuberculosis
estimates
GBD 2013 WHO 201382
Mortality
Key data sources or inputs • Vital registration (VR) data (2731 country-
years)
• Verbal autopsy (VA) data (166 site-years)
• Covariates
• VR data (2087 country-years)
• WHO 2013 tuberculosis incidence
estimates
• WHO 2012 tuberculosis case fatality rate
(CFR) estimates
• Covariates
Key adjustments to data • VR adjusted for estimated completeness in
each country-year
• VR and VA data adjusted based on detailed
analysis of garbage coding
• VR and VA data adjusted for
misclassification of tuberculosis-HIV
• Excluded VR data for South Africa and
Zimbabwe due to misclassification of
tuberculosis-HIV
• VR data adjusted for senile and ill-
defined cause of death
• VR data interpolated for missing data and
trailing or leading missing values with
exponential smoothing
• VR data adjusted for estimated
completeness in each country year
Modelling strategy All countries:
• Use the Cause of Death Ensemble
Modeling strategy (CODEm) to generate
mortality estimates from the VR and VA
data for all countries; covariates informed
the model; CODEm tests a wide range of
models and constructs an ensemble model
on the basis of performance of different
models judged with data held-out from
model -building
• Model fraction tuberculosis-HIV with the
fraction of tuberculosis-HIV in HIV
mortality from the VR data - HIV-mortality
estimates used to generate TB-HIV deaths
Countries with VR:
• Tuberculosis mortality directly from VR
data: 123 countries (45% estimated
global deaths)
Countries without VR with ten covariates available:
• Negative binomial model estimated
based on the 123 countries in the first
group; predictions from the model used
for 27 countries
Countries without VR without complete covariates:
• Mortality estimated by multiplying
estimated incidence multiplied by an
estimate of the case-fatality rate for all-
ages combined (67 countries)
• Regional case-fatality rates (CFR; high-
income, middle-income, and low-income
countries) generated from case
notifications by type (notified and non-
notified) and VR data (Bayesian linear
modelling done separately by region)
All countries:
• HIV plus tuberculosis incidence from
UNAIDS’ Spectrum model and estimated
CFR of tuberculosis mortality in HIV-
positive people (six CFRs corresponding
to six CD4 cell-count groups and one
CFR for cases on ART)
Uncertainty All countries:
• CODEm generates uncertainty intervals for
predicted death rates by sampling the
posterior distribution of each of the
component models in proportion to the
Countries with VR:
• Uncertainty was computed based on
sampling uncertainty
Countries without VR with ten covariates available:
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weight of each model in the ensemble;
mixed effects component model
uncertainty includes uncertainty in the
betas and the hierarchical random effects;
spatiotemporal Gaussian Process
Regression component models include
uncertainty from the mean prior and the
data variance
• Uncertainty interval coverage evaluated
objectively with out-of-sample predictive
validity
• Each country-year-age-sex draw adjusted
so it is consistent with the sum of all GBD
2013 causes and the all-cause mortality
estimate for that country-year-age-sex
group
• Uncertainty distributions across countries
were assumed to be independent
• Uncertainty estimated from the
uncertainty in the regression coefficients
Countries without VR without complete covariates:
• Mortality estimate uncertainty computed
with posterior distributions of CFR
(assumed time independent within
respective case categories [notified or
not, HIV positive or negative]) and
country-year distributions of estimated
incidence
All countries:
• Assumed uncertainty distribution
correlation across countries unknown
GBD 2013 differences • Tuberculosis mortality in all countries
based on models constructed from VR and
VA data
• VR and VA data corrected for garbage
coding and misclassification of HIV deaths
as tuberculosis deaths
• Fraction tuberculosis-HIV in HIV
empirically estimated with VR data
• Out-of-sample predictive validity testing
used to select the ensemble model for
estimating mortality in all countries
• The same approach was used for all
countries
• Sum of cause-specific mortality estimates
for a country-year-age-sex group must
equal all-cause mortality estimate at the
draw level (CoDCorrect algorithm)
• N/A
Incidence and prevalence
Key data sources and inputs • WHO tuberculosis case notifications (age-
sex-country-year specific)
• Tuberculosis prevalence surveys (27
national survey-years and 24 subnational
survey-years in 24 countries)
• Expert opinion and consultation on the
case-detection rate as reported by WHO
• GBD 2013 tuberculosis mortality estimates
• Pre-1994, case notifications for selected
countries (Australia, Canada, Germany,
UK, and Japan)
• GBD 2013 HIV prevalence estimates (CD4
and antiretroviral therapy [ART]-status
specific)
• Relative risks (RRs) of tuberculosis-HIV
compared with tuberculosis-only from
literature review (eight studies)
• WHO tuberculosis case notifications
(country-year specific)
• Prevalence surveys (about 19 national
years), adjusted for extra-pulmonary
tuberculosis and childhood tuberculosis
• Expert opinion and consultation of case
detection rate (CDR)
• Tuberculosis subnational surveillance
data, programmatic data, and inventory
studies
• Measure of access to health care and
performance of health system derived
from Demographic and Health Surveys
• RRs of tuberculosis-HIV compared with
tuberculosis-only (three studies)
• Population surveys of prevalence of HIV
in patients with tuberculosis, sentinel
HIV data, routine HIV testing of reported
tuberculosis cases
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• UNAIDS estimates of HIV prevalence in
children and in adults
Key adjustments to data • Correction of case notifications for missing
age groups, smear-unknown and relapsed
cases, and missing diagnostic categories
• Case notifications adjusted upwards for
underreporting with CDR
• Prevalence surveys adjusted for likely
proportion extra-pulmonary tuberculosis
missing in a survey with case notification
data
• Triangulation of expert opinion on under-
reporting CDR, subnational
administration data, programmatic data,
inventory studies, and DHS data
• Case notification data reviewed and
cleaned for underreporting,
misclassification and over-reporting
• Prevalence measurements reviewed and
adjusted for childhood tuberculosis and
extra-pulmonary tuberculosis
Modelling strategy All countries:
• Derivation of remission and excess
mortality from incidence to prevalence
ratio and CFR models with the adjusted
and historic case notifications, prevalence
data, and VR data
• Bayesian internally consistent estimation of
incidence, prevalence, excess mortality,
remission and mortality estimates in
DisMod-MR 2.0
• Estimation of the proportion of total
tuberculosis incidence and prevalence that
occurs in HIV-positive individuals with
GBD 2013 CD4-specific HIV prevalence
and CD4-specific RRs from a meta-
analysis in a population attributable
fraction calculation
Countries with regional workshops:
• Extrapolation of CDR estimates for 1997,
2003, and 2008-12 using a beta
distribution of plausible CDRs on three
data points per country
• Estimation of incidence from CDR and
case notifications for 96 countries.
Trends based on tuberculin surveys
(three countries) and mortality estimates
(40 countries)
Countries with national prevalence surveys:
• Incidence from empirical measurements
of disease prevalence and duration
estimates for two countries
High-income countries:
• Incidence from case notifications and
expert opinion or capture-recapture
modelling
All countries:
• Proportion of tuberculosis incidence that
is due to tuberculosis-HIV in UNAIDS’
Spectrum model based on population
surveys of HIV prevalence among
tubeculosis cases, sentinel HIV data, and
routine HIV testing of reported
tuberculosis cases
• Prevalence directly estimated from
national surveys adjusted for extra-
pulmonary and childhood tuberculosis or
indirectly from estimates of tuberculosis
incidence and duration
Uncertainty • Uncertainty in case notifications based on
expert reported upper and lower bounds of
the case-detection rate adjusted so that the
minimum interval is plus or minus 20
percentage points
• Uncertainty in corrected incidence,
remission rates, and excess mortality rates
estimated by use of draws from the
regression variance-covariance matrix of
the betas and draws from the random
effects distributions
• Prevalence survey uncertainty computed
from the sample size and sample design
• DisMod-MR generates posterior
distributions for incidence, prevalence,
• Uncertainty in incidence based on
primarily on uncertainty in expert
opinion on the case-detection rate
• Prevalence uncertainty based on either
sampling uncertainty in surveys and
assumptions about extra-pulmonary and
childhood tuberculosis (derived from
case notification data) or incidence
uncertainty and an assumed duration
• Assumed uncertainty distribution are
uncorrelated
• Estimates and their uncertainty are not
based on analysis of age-specific rates













Murray et al. Page 128
GBD 2013 WHO 201382
remission, and excess mortality that is a
function of data variance and model
parameter uncertainty
• Uncertainty distributions across countries
assumed to be uncorrelated
GBD 2013 differences • DisMod-MR 2.0 simultaneously
synthesizes all available data for incidence,
remission, excess mortality and prevalence
ensuring internal consistency
• Estimation of incidence, prevalence,
remission, and excess mortality is age-sex
specific
• All countries modelled with the same
approach
• N/A
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Table 10
Comparison between Global Burden of Disease 2013 verses WHO 2013 malaria estimates
GBD 2013 WHO110,162
Mortality
Country groupings 1 High malaria transmission countries in
Africa
2 Countries outside of Africa and low
malaria transmission African countries
3 Countries with mostly or only
Plasmodium vivax malaria
1 High transmission countries in Africa
2 Countries outside Africa and low malaria
transmission African countries
Key data sources • Verbal autopsy (VA) studies and vital
registration (VR) data
• For countries outside Africa and low
transmission African countries: NMCP reports
for case estimates, as described below, as well
as clinic records and reported malaria case
fatality data
• For high malaria transmission countries in
Africa: verbal autopsy studies, vital




• VR adjusted for completeness
• Adjustments for child deaths in VA and
VR for garbage coding
• None
Modelling strategy • Separate CODEM models for high malaria
transmission countries in Africa and
countries outside of Africa and low
malaria transmission African countries;
separate models for under 5 and ≥5 years
• CODEm covariates: Plasmodium
falciparum parasite rate (PfPr) from the
Malaria Atlas Project (2010), Lysenko
endemicity, WHO population-at-risk,
prevalence-weighted first-line drug
resistance, health-system access, indoor
residual spraying (IRS) and insecticide-
treated nets (ITN) coverage, rainfall,
education, and lagged gross domestic
product (GDP).
• Deaths for countries with mostly or only P
vivax malaria estimated with a negative
binomial model
For countries outside Africa and low transmission African
countries:
• Deaths estimated by multiplying malaria case
estimates by fixed case fatality ratios (045% in
Africa; 0.3% outside of Africa), based on
clinical malaria mortality and reported malaria
case fatality data
For high-transmission countries in Africa:
• Child deaths estimated using a verbal autopsy
multi-cause model (VAMCM) developed by
the WHO Child Health Epidemiology
Reference Group (CHERG),145 adjusted post-
hoc for the effect of bednets and use of
Haemophilus influenzae type b (Hib) vaccine
• Deaths in children aged 5 years or older:
“inferred from a relationship between levels of
malaria mortality in different age groups and
the intensity of malaria transmission”110
Uncertainty analysis For P falciparum countries:
• Uncertainty generated by CODEm
• CODEm generates uncertainty intervals
for predicted death rates by sampling the
posterior distribution of each of the
component models in proportion to the
weight of each model in the ensemble;
mixed effects component model
uncertainty includes uncertainty in the
betas and the hierarchical random effects;
spatiotemporal Gaussian Process
Regression component models include
uncertainty from the mean prior and the
data variance
For countries outside Africa and low transmission African
countries:
• Uncertainty in the case fatality rates assumed
arbitrarily to be a uniform distribution
between 0.225% and 0.675% for African
countries and between 0.15% and 0.45% for
outside of Africa
• Incidence rates: see section on morbidity
below
For high-transmission countries in Africa:
• For child deaths estimated by CHERG with
the VAMCM, “the bootstrap method was
employed to estimate uncertainty intervals by
re-sampling from the study-level data to
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• Uncertainty interval coverage assessed
objectively using out-of-sample predictive
validity
For P vivax countries:
• 1000 draws generated from the variance-
covariance matrix of coefficients from
negative binomial model
• Each country-year-age-sex draw adjusted
so it is consistent with the sum of all GBD
2013 causes and the all-cause mortality
estimate for that country-year-age-sex
group
• Uncertainty distributions across countries
were assumed to be independent
estimate the distribution of the predicted
percent of deaths due to each cause”110




• Malaria mortality in all countries based on
models constructed from VR and VA data
• VR and VA data corrected for garbage
coding in children
• Models include drug resistance and ITN
and IRS coverage
• Out-of-sample predictive validity testing
used to select the ensemble model for
estimating mortality in all countries
(except those with mostly or all P vivax
malaria)
• Sum of cause-specific mortality estimates
for a country-year-age-sex group must
equal all-cause mortality estimate at the
draw level (CoDCorrect algorithm)
• N/A
Morbidity
Country groupings As defined by Hay and colleagues163
1 Countries with reliable surveillance
systems (eight countries)
2 Countries with incomplete surveillance
systems (55 countries)
3 Countries with unreliable surveillance
systems (45 countries)
1 High-transmission countries in Africa
2 Countries outside Africa and low-malaria-
transmission African countries
Key data sources • For countries with reliable surveillance
systems and incomplete surveillance
systems: national malaria control
programme (NMCP) reports on the
number of cases, supplemented with
reported malaria case data at the
subnational levels for China and Mexico
• For countries with unreliable surveillance
systems: published epidemiological
studies of malaria incidence
• For countries outside Africa and for African
countries for which the quality of data were
considered adequate: NMCP reports on
malaria cases and nationally representative
household surveys on source of care
• For countries with unreliable surveillance





• For countries with reliable surveillance
systems: cases directly from NMCP report
data
• For countries with incomplete surveillance
systems: cases from NMCP data, adjusting
for completeness of reporting with health
system access proxy covariate using a
regression model
• For countries outside Africa and for African
countries for which the quality of data were
considered adequate: cases from NMCP report
data adjusted for proportion of cases receiving
a diagnostic test, completeness of reporting,
and health-care seeking with the fraction of
fever cases accessing facilities based on
Demographic and Health Surveillance Surveys
(DHS) and Multiple Indicator Cluster Survey
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• For countries with unreliable surveillance
systems: cases estimated using the relation
between studies of malaria incidence and
malaria mortality rates estimated from
CODEm with covariates for age group,
active versus passive case detection, inside
or outside Africa, and the ratio of site-
specific to national PfPR from MAP2010
(MICS), or other nationally representative
household surveys
• For high-transmission countries in Africa:
populations were classified as living at either
high, low, or no risk of malaria and then high,
low, or zero case-incidence rates were applied
to the populations living in each endemicity
class (procedure defined by Snow and
colleagues164). Estimates were adjusted post-
hoc for urban and rural differences and bednet
and IRS effects
• For countries with unreliable surveillance
systems: high, low, and zero case-incidence
rates were applied to populations classified as
living at either high, low, or no risk of malaria
defined according to climactic suitability (as
per the Mapping Malaria Risk in Africa
[MARA] project). Estimates were adjusted for
urban and rural differences, and the effect of
bednets and IRS
Uncertainty analysis For countries with unreliable surveillance systems (45
countries) and countries with incomplete surveillance
systems (55 countries):
• 1000 draws generated from the variance-
covariance matrix of coefficients from the
incidence regression
• Age pattern predicted with regression and
applied to non-age-specific WHO case
report data for countries with reliable
surveillance systems (eight countries)
For countries outside Africa and low-transmission African
countries:
• uncertainty in the completeness of reporting
assumed to be uniform for reported values
between 50% and 80% (low and mid value at
80% and high values at 100%) and triangular
distributions for values below 50% (low 0%,
mid and high 50%) and above 80% (low and
mid 80%, high 100%)
• Proportion of slide-positive cases assumed to
have a normal distribution with SD from a
least square regression of SDs on means
across countries
• Uncertainty in the proportion of population
with fever using health facilities that are
covered by the health-facility reporting system
of cases and proportion not seeking treatment:
based on survey SDs
• Final uncertainty based on bootstrap methods
assuming no correlation between sources of
uncertainty within a country
• Uncertainty distribution correlation across
countries unknown
For high-transmission countries in Africa:
• incidence rates by age and category of
transmission risk
• triangular distributions (with low, mid, and
high values based on median and interquartile
values as reported by Snow and colleagues164)
“truncated so that their lower limit did not fall
below 1”
• Adjustments for rural or urban differences and
for coverage of malaria preventive activities
(ITNs and IRS): not included in the
description of uncertainty methods
• Uncertainty distribution correlation across
countries unknown
GBD 2013 differences • Malaria cases were predicted with a
mortality-incidence model for countries
with unreliable surveillance systems
• N/A
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• Predictions are adjusted for detection
methods (active vs passive case detection)
The description of WHO estimation methods was based on the World Malaria Report 2008 and World Malaria Report 2011.
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